A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
Phase: PHASE3
Conditions: Type 1 Diabetes Mellitus
Sponsor: Eli Lilly and Company

Clinical Protocol I8B-MC-ITRM (a)
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin 
Lispro With an Open-Label Postprandial LY900014 Treatment Group, in 
Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 
Diabetes PRONTO-T1D
NCT03214367 
Approval Date: 22-May-2017

I8B-MC-ITRM (a) Clinical Protocol
Page 1
LY900014
Clinical Protocol I8B-MC-ITRM (a)
A Prospective, Randomized, Double-Blind Comparison of 
LY900014 to Insulin Lispro with an Open-Label Postprandial 
LY900014 Treatment Group, in Combination with Insulin 
Glargine or Insulin Degludec, in Adults with Type 1 Diabetes
PRONTO-T1D
[EudraCT number: 2015-005356-99]
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY900014, unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
Note to Regulatory Authorities:  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY900014
Study I8B-MC-ITRM is a Phase 3, prospective, randomized, double-blind, outpatient, 
multinational, multicenter, 3-treatment group, parallel, active-controlled study conducted in 
patients with type 1 diabetes currently using a multiple daily injection regimen.
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly: 16 Feb 2017
Amendment (a) Electronically Signed and Approved by Lilly
on approval date provided below.
Approval Date: 22-May-2017 GMT

I8B-MC-ITRM (a) Clinical Protocol
Page 2
LY900014
Table of Contents
Section
Page
1.
Synopsis .............................................................................................................................8
2.
Schedule of Activities .......................................................................................................13
3.
Introduction ......................................................................................................................20
3.1.
Study Rationale............................................................................................................20
3.2.
Background..................................................................................................................20
3.3.
Benefit/Risk Assessment..............................................................................................22
4.
Objectives and Endpoints..................................................................................................23
5.
Study Design.....................................................................................................................26
5.1.
Overall Design .............................................................................................................26
5.2.
Number of Participants.................................................................................................28
5.3.
End of Study Definition ...............................................................................................28
5.3.1.
Safety Follow-Up.................................................................................................28
5.4.
Scientific Rationale for Study Design...........................................................................28
5.5.
Justification for Dose ...................................................................................................29
6.
Study Population...............................................................................................................30
6.1.
Inclusion Criteria..........................................................................................................30
6.2.
Exclusion Criteria ........................................................................................................32
6.3.
Lifestyle Restrictions....................................................................................................34
6.4.
Screen Failures.............................................................................................................35
7.
Treatments........................................................................................................................36
7.1.
Treatments Administered .............................................................................................36
7.1.1.
Packaging and Labeling .......................................................................................36
7.1.2.
Medical Devices...................................................................................................37
7.2.
Method of Treatment Assignment ................................................................................37
7.2.1.
Selection and Timing of Doses.............................................................................37
7.2.1.1.
Target Glucose Values for Titration of Insulin Therapy ..................................37
7.2.1.2.
Basal Insulin Therapy.....................................................................................38
7.2.1.3.
Basal Insulin Titration ....................................................................................38
7.2.1.4.
Study Prandial Insulin Therapy.......................................................................39
7.2.1.5.
Transitioning off Study Prandial Insulin Therapy............................................42
7.3.
Blinding .......................................................................................................................42
7.4.
Dosage Modification....................................................................................................43
7.5.
Preparation/Handling/Storage/Accountability...............................................................43
7.6.
Treatment Compliance .................................................................................................43

I8B-MC-ITRM (a) Clinical Protocol
Page 3
LY900014
7.7.
Concomitant Therapy...................................................................................................44
7.8.
Treatment after the End of the Study............................................................................44
7.8.1.
Continued Access.................................................................................................44
7.8.2.
Special Treatment Considerations ........................................................................44
8.
Discontinuation Criteria ....................................................................................................45
8.1.
Discontinuation from Study Treatment.........................................................................45
8.1.1.
Permanent Discontinuation from Study Treatment ...............................................45
8.1.2.
Temporary Discontinuation from Study Treatment...............................................46
8.1.3.
Discontinuation of Inadvertently Enrolled Patients...............................................46
8.2.
Discontinuation from the Study....................................................................................46
8.3.
Lost to Follow-Up........................................................................................................47
9.
Study Assessments and Procedures ...................................................................................48
9.1.
Efficacy Assessments...................................................................................................48
9.1.1.
Primary Efficacy Assessments .............................................................................48
9.1.2.
Secondary Efficacy Assessments..........................................................................48
9.1.3.
Appropriateness of Assessments ..........................................................................49
9.1.4.
Study Procedures .................................................................................................49
9.1.4.1.
Electronic Clinical Outcomes Assessment ......................................................49
9.1.4.2.
Four-Point Self-Monitoring Blood Glucose ....................................................49
9.1.4.3.
Ten-Point Self-Monitoring Blood Glucose......................................................50
9.1.4.4.
Mixed-Meal Tolerance Test............................................................................50
9.1.4.5.
Diabetes Education and Nutritional Counseling ..............................................52
9.2.
Adverse Events ............................................................................................................52
9.2.1.
Serious Adverse Events........................................................................................53
9.2.1.1.
Suspected Unexpected Serious Adverse Reactions..........................................54
9.2.2.
Complaint Handling.............................................................................................54
9.3.
Treatment of Overdose.................................................................................................54
9.4.
Safety...........................................................................................................................55
9.4.1.
Hypoglycemia......................................................................................................55
9.4.2.
Severe Hypoglycemia ..........................................................................................56
9.4.3.
Electrocardiograms ..............................................................................................56
9.4.4.
Vital Signs ...........................................................................................................56
9.4.5.
Laboratory Tests ..................................................................................................56
9.4.6.
Safety Monitoring ................................................................................................56
9.5.
Pharmacokinetics .........................................................................................................56
9.6.
Pharmacodynamics ......................................................................................................57
9.7.
Pharmacogenomics ......................................................................................................57
9.7.1.
Whole Blood Samples for Pharmacogenetic Research..........................................57

I8B-MC-ITRM(a) Clinical Protocol
Page 4
LY900014
CCI
9.8. Biomarkers and Predictive or Other Analyses...............................................................57
9.8.1.
Samples for Immunogenicity Testing...................................................................58
9.9.
Health Economics........................................................................................................58
9.9.2.
Insulin Treatment Satisfaction Questionnaire.......................................................59
10. Statistical Considerations..................................................................................................61
10.1. Sample Size Determination..........................................................................................61
10.2. Populations for Analyses..............................................................................................61
10.3. Statistical Analyses......................................................................................................61
10.3.1. General Statistical Considerations........................................................................61
10.3.2. Treatment Group Comparability...........................................................................64
10.3.2.1. Patient Disposition..........................................................................................64
10.3.2.2. Patient Characteristics....................................................................................64
10.3.2.3. Concomitant Therapy.....................................................................................64
10.3.2.4. Treatment Compliance....................................................................................64
10.3.3. Efficacy Analyses................................................................................................64
10.3.3.1. Primary Analyses...........................................................................................64
10.3.3.1.1. Sensitivity Analyses for Missing Data.......................................................65
10.3.3.1.2. Additional Analyses for the Primary Endpoint..........................................66
10.3.3.2. Secondary Analyses........................................................................................66
10.3.3.3. Tertiary/Exploratory Analyses........................................................................67
10.3.4. Safety Analyses....................................................................................................67
10.3.5. Other Analyses.....................................................................................................68
10.3.5.1. Health Economics...........................................................................................68
10.3.5.2. Subgroup Analyses.........................................................................................69
10.3.6. Interim Analyses..................................................................................................69
11. References........................................................................................................................71
12. Appendices.......................................................................................................................73
CCI

I8B-MC-ITRM (a) Clinical Protocol
Page 5
LY900014
List of Tables
Table
Page
Table ITRM.1.
Objectives and Endpoints...............................................................................23
Table ITRM.2.
Treatment Regimens......................................................................................36
Table ITRM.3.
Target Glucose Values for Adjustment of Insulin Therapy.............................37
Table ITRM.4.
Basal Insulin Hypoglycemia Assessment .......................................................39
Table ITRM.5.
Summary of Basal Insulin Adjustments after Hypoglycemia 
Assessment....................................................................................................39
Table ITRM.6.
Prandial Insulin Doses and Corresponding Self Monitored Blood 
Glucose Values Pattern Adjustment Plan .......................................................41
Table ITRM.7.
LY900014 or Insulin Lispro Adjustment Algorithm Pattern Adjustment 
Plan ...............................................................................................................42
Table ITRM.8.
Concomitant Medications ..............................................................................44
Table ITRM.9.
Insulin to Carbohydrate Ratio for Determining the Prandial Insulin dose 
for the Mixed-Meal Tolerance Test:  For Use with Patients who use 
Pattern Adjustment to Determine Prandial Insulin Doses ...............................51
Table ITRM.10. Summary of Basal Insulin Adjustments after Hypoglycemia 
Assessment....................................................................................................99

I8B-MC-ITRM (a) Clinical Protocol
Page 6
LY900014
List of Figures
Figure
Page
Figure ITRM.1. Illustration of study design for Clinical Protocol I8B-MC-ITRM. ..................27

I8B-MC-ITRM(a) Clinical Protocol
Page 7
LY900014
List of Appendices
Appendix
Page
CCI
Appendix 1.
Abbreviations and Definitions........................................................................74
Appendix 2.
Clinical Laboratory Tests...............................................................................78
Appendix 3.
Study Governance Considerations..................................................................79
Appendix 4.
Hepatic Monitoring Tests for Treatment-Emergent Abnormality....................83
Appendix 6.
New York Heart Association Cardiac Disease Classification.........................85
Appendix 7.
Classification of Contraceptive Methods........................................................86
Appendix 8.
Insulin Lispro Antibody Follow-Up Assessment............................................87
Appendix 9.
Protocol Amendment I8B-MC-ITRM(a) Summary A Prospective, 
Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro 
with an Open-Label Postprandial LY900014 Treatment Group, in 
Combination with Insulin Glargine or Insulin Degludec, in Adults with 
Type 1 Diabetes
PRONTO-T1D..............................................................................................91

I8B-MC-ITRM (a) Clinical Protocol
Page 8
LY900014
1.
Synopsis
Title of Study: 
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label 
Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with 
Type 1 Diabetes PRONTO-T1D
Rationale: 
Prandial insulin with faster-onset and/or faster-offset characteristics might reduce glycemic excursions and the 
incidence of delayed postprandial hypoglycemia compared to currently available rapid-acting insulin analogs. 
Rapid-acting insulins, such as Humalog®, have been shown to have a more rapid onset of action compared to 
human insulin; however, the general consensus is that they are not rapid enough to match carbohydrate absorption, 
whether delivered by pump or syringe/pen injector, limiting efficacy.  An ultra-rapid-acting prandial insulin that 
would shift the pharmacokinetic (PK) and glucodynamic profiles of insulin to provide an even faster onset of action 
would better match carbohydrate absorption and allow for efficacious dosing immediately prior to meals or even
after meals. Ultra-rapid insulin (URI) could be useful in the treatment of type 1 diabetes (T1D) and type 2 diabetes
(T2D) in adults and children when given by multiple daily injections (MDI) or by continuous subcutaneous insulin 
infusion (CSII). 
The aim of this study is to demonstrate that an ultra-rapid formulation of insulin lispro, LY900014, is noninferior to 
insulin lispro on glycemic control as measured by change from baseline to Week 26 in hemoglobin A1c (HbA1c) in 
patients with T1D when administered in a double-blind manner as prandial insulin in combination with basal insulin 
glargine or insulin degludec.
Objectives/Endpoints:
Note:  Week 52 endpoints for the secondary objectives only apply to the blinded treatment arms of LY900014 and 
insulin lispro.  
Objectives
Endpoints
Primary Objective
1.
To test the hypothesis that LY900014 is
noninferior to insulin lispro on glycemic control
(noninferiority margin [NIM]=0.4% for
hemoglobin A1c [HbA1c]) in patients with T1D,
when administered as prandial insulin (0 to
2 minutes prior to the meal), in combination with
basal insulin glargine or insulin degludec for 26
weeks
1.
Difference between LY900014 and insulin lispro
in change from baseline to Week 26 in HbA1c
Multiplicity Adjusted Objectives
2.
To test the hypothesis that LY900014 is superior
to insulin lispro in controlling 1-hour postprandial
glucose (PPG) excursions, when administered as
prandial insulin
2.
Difference between LY900014 and insulin lispro
in the 1-hour PPG excursion (serum glucose
measured 1 hour after the start of the meal minus
fasting serum glucose) from a mixed-meal
tolerance test (MMTT) at Week 26

I8B-MC-ITRM (a) Clinical Protocol
Page 9
LY900014
Multiplicity Adjusted Objectives (continued)
3.
To test the hypothesis that LY900014 is superior 
to insulin lispro in controlling 2-hour PPG 
excursions, when administered as prandial insulin 
3.
Difference between LY900014 and insulin lispro 
in the 2-hour PPG excursion (serum glucose 
measured 2 hours after the start of the meal minus 
fasting serum glucose) from an MMTT at 
Week 26
4.
To test the hypothesis that LY900014 is superior 
to insulin lispro on improving glycemic control 
(HbA1c) when administered as prandial insulin
4.
Difference between LY900014 and insulin lispro 
in change from baseline to Week 26 in HbA1c 
5.
To test the hypothesis that LY900014 
administered as postprandial insulin 20 minutes 
after the start of a meal (LY900014+20), is 
noninferior to insulin lispro, administered as 
prandial insulin, on glycemic control (NIM=0.4% 
for HbA1c) 
5.
Difference between LY900014+20 and insulin 
lispro in change from baseline to Week 26 in 
HbA1c
Other Secondary Objectives 
6.
To compare LY900014+20 with insulin lispro and 
LY900014 with respect to 1-hour and 2-hour PPG 
excursions
6.
1- and 2-hour PPG excursions from an MMTT at 
Week 26
7.
To compare the glycemic control of LY900014 
with LY900014+20
7.
Change from baseline HbA1c values at Week 26
8.
To compare LY900014, LY900014+20, and 
insulin lispro on the rate of severe hypoglycemic 
events 
8.
Rate (events/patient/100 years) of severe 
hypoglycemic events from baseline through 
Week 26 and Week 52
9.
To compare LY900014, LY900014+20, and 
insulin lispro with respect to the incidence and 
rate of documented symptomatic postmeal 
hypoglycemia
9.
Rate (events/patient/year and/or 
events/patient/30 days) and incidence (percent of 
patients with at least 1 event) of documented 
symptomatic postmeal hypoglycemia within 1 and 
2 hours after start of a meal from Week 12 
through Week 26, Week 0 through Week 26, 
Week 26 through Week 52, and Week 0 through 
Week 52
10. To compare LY900014, LY900014+20, and 
insulin lispro with respect to the incidence and 
rate of documented symptomatic hypoglycemia
10. Rate (events/patient/year and/or 
events/patient/30 days) and incidence (percent of 
patients with events) of documented symptomatic 
hypoglycemic events from Week 12 through 
Week 26, Week 0 through Week 26, Week 26 
through Week 52, and Week 0 through Week 52
11. To compare LY900014, LY900014+20, and 
insulin lispro with respect to 1,5-Anhydroglucitol 
(1,5-AG) 
11. Change from baseline 1,5-AG values at Week 26
and Week 52
12. To compare LY900014, LY900014+20, and 
insulin lispro with respect to 10-point self-
monitored blood glucose (SMBG) profiles
12. Change from baseline 10-point SMBG values at 
Week 26 and Week 52
13. To compare LY900014, LY900014+20, and 
insulin lispro with respect to total, basal, and 
prandial insulin dose 
13. Change from baseline in total, basal and prandial 
insulin doses and prandial/total insulin dose ratios
at Week 26 and Week 52
Other Secondary Objectives (continued)

I8B-MC-ITRM (a) Clinical Protocol
Page 10
LY900014
14. To compare LY900014, LY900014+20, and 
insulin lispro with respect to diabetes treatment 
satisfaction as measured by the Insulin Treatment 
Satisfaction Questionnaire (ITSQ)
14. Change from baseline in ITSQ regimen 
inconvenience and lifestyle flexibility domain 
scores at Week 26 and Week 52
15. To compare LY900014, LY900014+20, and 
insulin lispro with respect to the proportion of 
patients achieving HbA1c targets
15. The proportion of patients with HbA1c <7% and 
≤6.5% at Week 26 and Week 52
16. To compare the glycemic control of LY900014 
and insulin lispro
16. Actual and change from baseline to Week 52 in 
HbA1c
Summary of Study Design:  
Study I8B-MC-ITRM is a Phase 3, prospective, randomized, double-blind, outpatient, multinational, multicenter 
3-treatment group, parallel, active-controlled study in patients with T1D currently using an MDI regimen.
Treatment Groups and Duration:  
The study includes a 1-week screening period and an 8-week lead-in period.  In 2 of the treatment groups, 
LY900014 and insulin lispro will be administered immediately (0-2 minutes) prior to each meal in a double-blind 
manner. Patients in these groups will complete a 52-week treatment period (with primary endpoint at 26 weeks), and 
a 4-week safety follow-up period.  A third open-label treatment group consists of LY900014 administered 20 
minutes after the start of a meal (LY900014+20).  Patients in this treatment group will complete a 26-week 
treatment period and the 4-week safety follow-up period.  
All patients who complete the 4-week safety follow-up visit (Visit 801) and have treatment-emergent insulin lispro 
antibodies that have not returned to prespecified baseline range (Visit 2) will be asked to participate in follow-up to 
monitor insulin lispro antibody levels.  Study visits will be scheduled at approximately 3-month intervals for up to 
26 weeks from Visit 801 or until insulin lispro antibodies return to baseline range, whichever occurs sooner.
Number of Patients:
Approximately 1500 participants will be screened to achieve 1199 randomized patients and 1020 patients 
completing 26 weeks of treatment, with approximately 646 patients completing 52 weeks.  
Statistical Analysis:
The primary analysis is for the treatment period through Week 26.  
Efficacy analyses will be conducted on all randomized patients according to the treatment the patients are assigned.  
The analyses for the primary and multiplicity adjusted objectives will be performed for the efficacy estimand 
including data collected prior to permanent discontinuation of investigational product (IP) through Week 26 and for 
the ITT estimand (treatment regimen estimand) including all data collected through Week 26 regardless of IP use.  
When change from baseline is included as a response variable of analysis models, the patient will be included in the 
analysis only if a baseline and at least 1 postbaseline measurement are available.  Selected efficacy analyses will 
also be conducted using the Per Protocol (PP) and Completer populations.  Week 52 analyses will include the 
LY900014 and insulin lispro treatment arms and only be performed for the efficacy estimand.  
Safety analyses will be conducted on the Safety population.  Analyses of adverse events (AEs) will include 2 sets of 
analyses, unless otherwise specified.  The first set of analyses will include data collected prior to permanent 

I8B-MC-ITRM (a) Clinical Protocol
Page 11
LY900014
discontinuation of IP.  The second set of analyses will include all data collected during the course of the entire study 
regardless of IP use. Analyses of hypoglycemia will be conducted on data collected prior to permanent 
discontinuation of IP, while analyses for post-treatment may be conducted as needed. Analyses of safety laboratory 
measurements will be performed on all data collected during the planned treatment period regardless of IP use.
Week 26 analyses will include treatment comparisons among three treatment groups. Week 52 analyses will also 
include data collected during the follow-up visit for LY900014 and insulin lispro.  All data collected including the 
follow-up visit will be summarized for LY900014+20.
Baseline is defined as the last nonmissing measurement at or before the randomization visit (Visit 8), unless 
otherwise specified.
For the US Food and Drug Administration (FDA) submission, the primary analysis method will use the copy 
reference approach to impute missing data based on multiple imputations with a pattern mixture model.  This 
analysis is for the ITT estimand that will include all data collected from randomization through Week 26, regardless 
of IP use.  The reference will be all observed data from the randomized patients in the same treatment arm who 
discontinue IP and complete the study without missing data.  After imputation, the primary efficacy comparison will 
be based on the contrast between LY900014 and insulin lispro from the analysis of covariance (ANCOVA) analysis 
of change from baseline to Week 26 in HbA1c using all randomized patients.  The model for this analysis will 
include the fixed class effects of treatment and strata (pooled country, type of basal insulin, and prandial insulin 
dosing plan), and the continuous, fixed covariate of baseline value.
If there are only a limited number of patients in the reference group as described above that leads to a failure in 
performing the proposed multiple imputation analysis, the reference will be changed to include all observed data 
from all randomized patients in the same treatment arm who complete the study without missing data.  
For non-FDA submissions and publications, the primary efficacy comparison will be based on the contrast between 
LY900014 and insulin lispro at Week 26 (Visit 18) from the mixed-effect model repeated measure (MMRM)
analysis of change from baseline in HbA1c including data collected from all randomized patients prior to permanent 
discontinuation of IP through Week 26 (efficacy estimand).  The model for this analysis will include the fixed class 
effects of treatment and strata (pooled country, type of basal insulin, and prandial insulin dosing plan), visit, and 
treatment-by-visit interaction, and the continuous, fixed covariate of baseline value. 
For both primary analysis approaches, LY900014 will be declared noninferior to insulin lispro if the upper limit of 
the 2-sided 95% confidence interval (CI) for the least squares (LS) mean difference in the change from baseline in 
HbA1c for LY900014 minus insulin lispro is below +0.4%.  In addition, the 95% CI for the treatment difference will 
be compared to an alternative NIM of +0.3%.  Both estimands will be tested at the full significance level of 0.05.  
The ANCOVA and MMRM analyses will include data from all 3 treatment groups; however, the contrasts between 
LY900014+20 and insulin lispro and between LY900014 and LY900014+20 are not part of the primary efficacy 
comparisons.
A graphical approach (Bretz et al. 2011) for multiple comparisons will be used to strongly control the overall Type I 
error (2-sided alpha level of 0.05) for testing the treatment effect for the primary and the following multiplicity 
adjusted objectives:  superiority of LY900014 compared with insulin lispro for 1-hour PPG excursion at Week 26, 
2-hour PPG excursion at Week 26, and change from baseline to Week 26 in HbA1c; and noninferiority of 
LY900014+20 to insulin lispro in change from baseline to Week 26 in HbA1c.  The same graphical testing scheme 
will be applied for both the efficacy estimand and ITT estimand.

I8B-MC-ITRM(a) Clinical Protocol
Page 12
LY900014
An analysis of covariance (ANCOVA) model with strata (pooled country, type of basal insulin,baseline HbA1c 
strata [(≤7.5%, >7.5%],and prandial insulin dosing planduring the study), and treatment as fixed effects and 
baseline as a covariate will be used to analyze the 1-hour and 2-hour PPG excursions.  However, if the percentage of 
the patients with missing MMTT data at baseline is higher than 15%, a constrained longitudinal data analysis model 
(Liu et al. 2009; Lu 2010) will be used instead.  Analyses details will be documented in the statistical analysis plan 
(SAP).
Hypoglycemia rates will be summarized for periods of 30 days, 1 year, and 100 years (severe hypoglycemia only).  
The rate of severe hypoglycemia per 100 years will be compared between treatment groups using the empirical 
method.  For each of the other categories of hypoglycemia, the number of hypoglycemia events during a specific 
period (rate) after randomization (for example, 0-12weeks of treatment period) will be analyzed by using a negative 
binomial regression model.  The model will include treatment and the baseline hypoglycemia rate (measured during 
lead-in) as a covariate.  An offset defined as the log transformation of treatment exposure in the specific period 
(days)/365.25 days (or 30 days) will be included in the model to estimate the rate of hypoglycemia per year (or per
30 days). The proportion of patients with at least 1 hypoglycemic event in each category (incidence) during a 
specific period after randomization will be analyzed using a logistic regression model including treatment and 
baseline hypoglycemia rate value in the model. 
Continuous safety variables, as well as the change from baseline for these variables, will be analyzed by MMRM or 
ANCOVA models.  For categorical variables, Fisher’s exact test or Pearson’s chi-square test will be used to 
compare treatment groups unless otherwise specified. 
Change from baseline to last-observation-carried forward endpoints for the 
 ITSQ, and 
 
 will be analyzed using ANCOVA models. 
References:
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for multiple 
comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom J. 2011;53(6):894-913.
Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent variable in analyses 
of change from baseline in clinical trials? Stat Med. 2009;28(20):2509-2530.
Lu K. On efficiency of constrained longitudinal data analysis versus longitudinal analysis of covariance. Biometrics
CCI
. 
2010;66(3):891-896.
CCI

I8B-MC-ITRM Clinical Protocol
Page 13
LY900014
2. Schedule of Activities
Study Procedure
Study 
Screening
Lead-In Period
Intensive Titration Period
Maintenance 
Period
Long Term 
Maintenance Period
(Double Blind Arms 
Only)
Safety
Follow-
Up
ED
Primary Treatment Period
eCRF Visit Number
1
2
3a
4a
5
6a
7
8
9a
10
11
12
a
13
14
a
15
16
17
18
19
20
21
22
801
EDb
Visit Window 
(± days)
3
3
3
3
3
3
4
3
3
7
7
7
7
7
7
7
7
7
7
7
7
7
Time on Study 
Relative to First 
Active Treatment 
Dose (weeks)
-9
-8
-7
-6
-4
-2
-1
0
1
2
4
6
8
10
12
18
22
26
32
39
46
52
56 (30)c
Informed consent 
signed
X
IWRS
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Patient eligibility 
review 
X
Randomizationd
X
Telephone call for 
visit reminder or 
informing patient of 
completion in the 
study
X
Clinical Assessments
Patient demographics
X
Medical historyand  
preexisting 
conditions
X
Physical exam/height
X
Concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events and 
product complaints
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

I8B-MC-ITRM Clinical Protocol
Page 14
LY900014
Study Procedure
Study 
Screening
Lead-In Period
Intensive Titration Period
Maintenance 
Period
Long Term 
Maintenance Period
(Double Blind Arms 
Only)
Safety
Follow-
Up
ED
Primary Treatment Period
eCRF Visit Number
1
2
3a
4a
5
6a
7
8
9a
10
11
12
a
13
14
a
15
16
17
18
19
20
21
22
801
EDb
Visit Window 
(± days)
3
3
3
3
3
3
4
3
3
7
7
7
7
7
7
7
7
7
7
7
7
7
Time on Study 
Relative to First 
Active Treatment 
Dose (weeks)
-9
-8
-7
-6
-4
-2
-1
0
1
2
4
6
8
10
12
18
22
26
32
39
46
52
56 (30)c
Body weighte
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs: blood 
pressure/pulse ratef
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
ECG
g (12-lead; local)
X
Diabetes and 
nutrition counselingh
X
Transfer to insulin 
lisproi
X
Transfer to allowed 
study basal insulin
regimenj
X
Basal and prandial 
insulin dose 
assessmentk
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Titrate basal insulink
X
X
X
X
X
X
Titrate prandial
insulinl
X
X
X
X
X
X
X
X

I8B-MC-ITRM Clinical Protocol
Page 15
LY900014
Study Procedure
Study 
Screening
Lead-In Period
Intensive Titration Period
Maintenance 
Period
Long Term 
Maintenance Period
(Double Blind Arms 
Only)
Safety
Follow-
Up
ED
Primary Treatment Period
eCRF Visit Number
1
2
3a
4a
5
6a
7
8
9a
10
11
12
a
13
14
a
15
16
17
18
19
20
21
22
801
EDb
Visit Window 
(± days)
3
3
3
3
3
3
4
3
3
7
7
7
7
7
7
7
7
7
7
7
7
7
Time on Study 
Relative to First 
Active Treatment 
Dose (weeks)
-9
-8
-7
-6
-4
-2
-1
0
1
2
4
6
8
10
12
18
22
26
32
39
46
52
56 (30)c
Ancillary Supplies/Diaries/IP
Dispense blood 
glucose meter and
ancillary supplies and 
complete trainingm,n
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Dispense eCOA and 
complete trainingn
X
Train on collecting 4-
and 10-point SMBG 
profilesn
X
Review 4-point 
SMBG profiles 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Remind patient of 10-
point SMBG 
requirementso
X
X
X
X
X
X
X
X
Review 10-point 
SMBG Profiles
X
X
X
X
X
X
X
Xp
Review/discuss hypo 
data 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Dispense IP 
X
X
X
X
X
X
X
X
X
X
X
X
Return of eCOA 
devices
X
X

I8B-MC-ITRM Clinical Protocol
Page 16
LY900014
Study Procedure
Study 
Screening
Lead-In Period
Intensive Titration Period
Maintenance 
Period
Long Term 
Maintenance Period
(Double Blind Arms 
Only)
Safety
Follow-
Up
ED
Primary Treatment Period
eCRF Visit Number
1
2
3a
4a
5
6a
7
8
9a
10
11
12
a
13
14
a
15
16
17
18
19
20
21
22
801
EDb
Visit Window 
(± days)
3
3
3
3
3
3
4
3
3
7
7
7
7
7
7
7
7
7
7
7
7
7
Time on Study 
Relative to First 
Active Treatment 
Dose (weeks)
-9
-8
-7
-6
-4
-2
-1
0
1
2
4
6
8
10
12
18
22
26
32
39
46
52
56 (30)c
Patient returns used 
and unused study 
drug supplies
X
X
X
X
X
X
X
X
X
X
X
X
X
Drug accountability
X
X
X
X
X
X
X
X
X
X
X
X
X
Laboratory Assessments
Patient fasts prior to 
visit
X
X
X
X
X
MMTTq
X
X
Urinalysis panel
X
Pregnancy testr
X
X
Follicle-stimulating 
hormone tests
X
Chemistry panel
X
X
X
X
X
Fasting Serum 
Glucose
X
Hematology
X
X
X
X
X
1,5-Anhydroglucitol
X
X
X
X
X
X
X
Hemoglobin A1c
X
X
X
X
X
X
X
X
X
X
X
Lipid profile
X
X
X
X
Pharmacogenetic 
samplet
X

I8B-MC-ITRM Clinical Protocol
Page 17
LY900014
Study Procedure
Study 
Screening
Lead-In Period
Intensive TitrationPeriod
Maintenance 
Period
Long Term 
Maintenance Period
(Double Blind Arms 
Only)
Safety
Follow-
Up
ED
Primary Treatment Period
eCRF Visit Number
1
2
3a
4a
5
6a
7 
8
9a
10 
11
12
a
13
14
a
15 
16 
17 
18 
19 
20 
21 
22 
801
EDb
Visit Window 
(± days)
3
3
3
3
3 
3 
4
3 
3 
7
7 
7
7 
7 
7 
7 
7 
7 
7 
7 
7 
7
Time on Study 
Relative to First 
Active Treatment 
Dose (weeks)
-9
-8
-7
-6
-4
-2 
-1 
0
1 
2 
4
6 
8
10 
12 
18 
22 
26 
32 
39 
46 
52 
56(30)c
Nonpharmacogenetic 
biomarker storage 
samples 
X
X
X
Anti-insulin lispro 
antibodies
X
X
X 
X
X
X
X 
Xu
X
Health Outcomes Questionnairesv
ITSQ
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
CCI

I8B-MC-ITRM Clinical Protocol
Page 18
LY900014
Schedule of Activities
Abbreviations:  ECG = electrocardiogram; eCOA = electronic clinical outcomes assessment, eCRF = electronic case report form; ED = early discontinuation; 
 glucose; hypo =hypoglycemia; IP = investigational product; ITSQ = Insulin Treatment 
Satisfaction Questionnaire; IWRS = interactive web response system; MMTT = mixed-meal tolerance test; SMBG = self-monitored blood glucose;V = visit; 
a Telephone visits areindicated by shaded columns.  Activities include: 
Record visit in the IWRS.
Collect adverse events and concomitant medications.
Review blood glucose readings and study drug doses. 
Adjustprandial insulinor basalinsulin dosesas needed.
Review hypoglycemic events. 
Provide reminders regarding scheduled visits, fasting, and SMBG profiles, as applicable.
b Patients who have been randomized will be asked to return for the ED visit in a fasting stateunless patient is already fasting and at the site when the decision 
to discontinue is made.  Patients who discontinue during the lead-in period prior to randomizationwho are not already at the site,will be asked to return for 
the EDin a nonfasting state and all activities should be completed except for laboratory testsand questionnaires (ITSQ, 
). 
c Patients randomized to the open-label treatment groupwill complete the study at Week 30unless patientcontinues into the insulin antibody assessment 
period.  It is recommended that the first insulin lispro antibody follow-up visit (Visit 802[Appendix 8]) be scheduled for all study patients, regardless of 
treatment-emergent antibody status.  Visit 802 should occur approximately13 weeks after Visit 801.
d Randomization should occur after all Visit 8 procedures including MMTT.  If MMTT is rescheduled post Visit 8, randomization should not occur until 
baseline MMTT is completed.  The patientwill administer their first dose of study insulin with the first mealafter the MMTT has been completed and 
randomization has occurred.  
e Patients should be advised to remove their shoes and empty their pockets before the body weight is obtained.
f Vital sign measurements must be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing.  These measurements 
should be determined after patients have been seated quietly for at least 5 minutes in a chairwith feetonthe floor.  The arm used for blood pressure 
measurement should be supported at heart level.  
g Patients must be supine for approximately 5 to 10 minutes before ECG collection and remain supine but awake during ECG collection.
h Initial training at Visit 2 will include diabetes education and nutrition counseling.  Appropriate site personnel willadminister training and education using 
locally approved diabetes education/training materials or other materialsprovided by the Sponsor.  Patients may be provided abbreviated training and 
education at visits following Visit 2 as appropriate.
i Only applies to patients on insulin glulisine or insulin aspart.
j Patients will be transferred to a study basal insulinregimen at Visit 2.  Investigators will determine the appropriate basal insulin regimen for each patient. It is 
expected that most of the basal insulin dose adjustments should occur during the lead-in period.  However,basalinsulin titration may continue during the 
intensive titration period for patients who need more intensification to achieve glycemic targets.  Basal insulin dose adjustments during the maintenance 
period should be made for safety reasons such as hypoglycemia and unacceptable hyperglycemia. 
k
CCI
Assessments of the basal insulin dose should be made,at minimum,weekly during the lead-in period, including Weeks -5 and -3. Assessment of the prandial 
insulin dose should be made,at minimum,weekly during the initial 12 weeks after randomization, including Weeks 3, 5, 7, 9,and 11. 
CCI
CCI
CCI

I8B-MC-ITRM Clinical Protocol
Page 19
LY900014
l
During the lead-in period, prandial doses, correction factors, and insulin to carbohydrate ratios should be evaluated and adjustments should be made for safety 
reasons such as hypoglycemia and unacceptable hyperglycemia.  During the intensive titration period, prandial insulin dose should be adjusted in order to 
meet the target SMBG levels.  Further adjustments during the maintenance period should be made for safety reasons such as hypoglycemia and unacceptable 
hyperglycemia.   
m Glucose monitoring supplies will be dispensed at other visits, as needed.
n
Training may be repeated at other visits, as needed.
o
Patients in all 3 study arms should be instructed to perform three 10-point SMBG profiles during a 2-week period.  The 10-point profile is completed over a 1-
day period, preferably on 3 nonconsecutive days (weekdays and weekends).  Ten-point SMBG profiles should not be performed on the day of MMTT.
p
Review of 10-point SMBG profiles at the ED visit will take place only for patients randomized into the study.
q
MMTT can occur 0 to 4 days prior to the visit, and patient must be fasting prior to start of the MMTT.
r
Serum pregnancy test must be performed in women of childbearing potential at Visit 1 followed by a urine pregnancy test within 24 hours prior to IP 
exposure at randomization (Visit 8) and at other times at the investigator’s discretion. When required per local regulations and/or institutional guidelines, 
local pregnancy testing will occur at mandatory times during the study treatment period.
s
Follicle-stimulating hormone test must be performed at Visit 1 for a postmenopausal woman who is between 50 and 54 years of age (inclusive) with an intact 
uterus, not on hormone therapy, and who has had at least 6 months of spontaneous amenorrhea. 
t
Pharmacogenetic sample can be collected at any other visit if not collected at Visit 8
u
Patients with treatment-emergent insulin lispro antibodies measured at Visit 801 that have not returned to prespecified baseline range (Visit 2), will be asked 
to undergo additional antibody monitoring as described in Appendix 8.  This follow-up assessment also applies to any patient who discontinues study insulin 
treatment prior to the end of the planned treatment period who has a treatment-emergent antibody response that has not returned to baseline range by Visit 
801.  It is recommended that the first insulin lispro antibody follow-up visit (Visit 802) be scheduled for all study patients, regardless of treatment-emergent 
antibody status.
v
Health outcomes questionnaires will be administered at the study sites based on the availability of appropriate translations.  The questionnaires should be 
administered prior to other study procedures except at Visit 8 and Visit 18 when questionnaires may be administered following the start of the MMTT.

I8B-MC-ITRM Clinical Protocol
Page 20
LY900014
3.
Introduction
3.1.
Study Rationale
Prandial insulin with faster-onset and/or faster-offset characteristics might reduce glycemic
excursions and decrease the incidence of delayed postprandial hypoglycemia compared to 
currently available rapid-acting insulin analogs. The insulin analog, insulin lispro (Humalog®), 
has been shown to be absorbed more quickly than regular human insulin (Humalog package 
insert, 2015).  In healthy volunteers given subcutaneous (SC) doses of insulin lispro ranging 
from 0.1 to 0.4 U/kg, peak serum levels were seen 30 to 90 minutes after dosing. Rapid-acting 
insulins have been shown to have a more rapid onset of action compared to human insulin; 
however, the general consensus is that they are not rapid enough to match carbohydrate 
absorption and many patients are unable to achieve optimal glycemic control.  An ultra-rapid-
acting prandial insulin with pharmacokinetic (PK) and glucodynamic (GD) profiles that 
demonstrate faster absorption and onset of action may better match carbohydrate absorption and
lead to improved postprandial control.  The time action profile of rapid-acting insulin could be 
enhanced through the addition of excipients to an existing formulation to increase capillary blood 
flow and/or enhance vascular permeability.  An ultra-rapid insulin (URI) would be useful in the 
treatment of type 1 diabetes (T1D) and type 2 diabetes (T2D) when delivered by multiple daily 
injections (MDI), by continuous SC insulin infusion (CSII), and in the development of closed 
loop insulin delivery systems.
The aim of this study is to demonstrate that an ultra-rapid formulation of insulin lispro, 
LY900014, is noninferior to insulin lispro on glycemic control as measured by change from 
baseline to Week 26 in hemoglobin A1c (HbA1c) in patients with T1D, when administered in a 
double-blind manner as prandial insulin in combination with basal insulin glargine or insulin 
degludec.  
3.2.
Background
T1D is an autoimmune disease mediated by a combination of genetic and environmental triggers 
resulting in lymphocytic infiltration of pancreatic islets, destruction of beta cells, and lifelong 
dependency on exogenous insulin.  T1D prevalence is near 1 in 300 and its incidence is steadily 
increasing worldwide (3% per year [Gan et al. 2012]).  
There have been many advances in the treatment of T1D in the last 20 years; however, reaching 
and maintaining glycemic goals remains challenging even under intensive insulin therapy 
regimens.  Only approximately 30% of insulin requiring diabetes patients are able to reach the 
goal HbA1c target of <7% (Stark-Casagrande et al. 2013). Currently available rapid-acting 
insulin analogs continue to be unable to match the kinetics of physiological postmeal insulin 
secretion, which is biphasic.  Normal first phase insulin response is a rapid but short-lived 
increase in secretion, which is then followed by a more slowly developing prolonged increase 
(Barrett et al. 2016).  First phase insulin release prevents the rapid development of postprandial 
hyperglycemia while second phase release of insulin ensures that glucose enters tissues in a 
steady, controlled manner throughout the late postprandial period.  Thus, there remains a need to 

I8B-MC-ITRM Clinical Protocol
Page 21
LY900014
continue to develop formulations with a time action profile that more closely approximates that 
of endogenous insulin section. 
Ideally, currently available rapid-acting insulin analogs should be injected 10 to 15 minutes prior
to meal consumption in order to control postprandial glucose (PPG).  However, many persons
inject their rapid-acting insulin at the time of the meal or after the meal.  According to survey 
data from the T1D Exchange on the timing of prandial insulin injection, 16.3% of patients
indicated that they inject 15 minutes prior to meals, 33% inject 1 to 14 minutes prior to meals, 
38.6% inject at the time of the meal, and 12.1% inject after meals.  Because patients often inject 
later than recommended there is a greater mismatch between insulin action and postprandial 
blood glucose (BG) elevations. With postmeal dosing, the mismatch between the rise in BG and 
the onset of insulin action is even more pronounced.  For the development of a URI, it will be 
important to understand the relationship between time action profile of the insulin, insulin 
injection timing, and meal timing in order to maximize improvements in postprandial glycemic 
control and minimize hypoglycemia risk. A URI with higher early insulin concentration and 
peak exposure, and shorter duration should improve early postprandial control and limit 
postmeal hyperglycemia, while reducing late postprandial hypoglycemia due to lower insulin 
exposure.  
HbA1c provides an integrated measurement of both fasting and postprandial glycemic control
and is the most reliable marker for overall glucose exposure.  Elevation in HbA1c is the best 
predictor of diabetes complications. Control of both fasting and postprandial hyperglycemia is 
essential to reach HbA1c goals. The relative contribution of postprandial hyperglycemia is
predominant with moderate to fairly well controlled HbA1c levels (Monnier et al. 2003). 
A new pharmaceutical innovation that may allow more effective control of PPG levels is 
LY900014, a new formulation of insulin lispro developed as an ultra-rapid acting insulin with a 
faster onset of action and shorter duration of action compared to currently available rapid-acting 
insulin analogs.  The changes in PK and GD characteristics are achieved by coformulating 
insulin lispro with treprostinil and ingredients Generally Recognized As Safe (GRAS) by the 
Food and Drug Administration (FDA) as excipients.
LY900014 is a formulation of insulin lispro that contains the prostacyclin analog treprostinil, 
citrate, and other excipients.  Treprostinil as an excipient enhances the absorption of insulin 
lispro by local vasodilatation rather than as an active pharmaceutical ingredient that elicits a 
systemic effect.  Treprostinil is a prostacyclin analog administered either by inhalation 
(Tyvaso®), intravenous (IV) infusion, or continuous SC infusion (Remodulin®) for the 
treatment of symptomatic pulmonary arterial hypertension, and has been approved in the United 
States since 2002 (Remodulin package insert, 2014) and in Europe since 2005 (PMR [WWW]).  
Sodium citrate, an excipient that speeds insulin absorption, is also included in the formulation to 
further enhance the absorption of insulin lispro.  Sodium citrate and the other excipients in the 
LY900014 formulation are listed in the FDA GRAS food additives database and in the FDA 
Inactive Ingredients in Approved Drugs database. Furthermore, the excipient concentration in 
LY900014 is within the limits identified for approved drug products in the FDA Inactive 
Ingredients in Approved Drugs database.

I8B-MC-ITRM Clinical Protocol
Page 22
LY900014
Please refer to the Humalog local product labeling (for example, Humalog package insert, 2015; 
Humalog Summary of Product Characteristics, 2016) for more information regarding insulin 
lispro. 
The Investigator’s Brochure (IB) describes the clinical and nonclinical development of 
LY900014. 
3.3.
Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks of insulin lispro may 
be found in the country-specific product labeling (for example, Patient Information Leaflet, 
Package Insert, or Summary of Product Characteristics).
Across all doses in the Eli Lilly and Company (Lilly) clinical studies that have evaluated 
treprostinil as a local vasodilator with or without insulin lispro, there was no clinically significant 
increase in those adverse events (AEs) associated with systemic absorption of treprostinil, as 
described in the Remodulin package insert (2014) (that is, headache, diarrhea, nausea, jaw pain, 
vasodilatation, rash, edema, anorexia, vomiting, asthenia, abdominal pain, and hypotension).  
The exposures of treprostinil in LY900014 for participants in upcoming and future clinical trials 
are expected to be much lower than those observed in the dose ranges previously explored with 
SC bolus administration of treprostinil and are expected to be substantially lower than those 
observed in the treatment of pulmonary artery hypertension (PAH).  
More information about the known and expected benefits, risks, serious AEs (SAEs), and 
reasonably anticipated AEs of LY900014 can be found in the IB.  

I8B-MC-ITRM Clinical Protocol
Page 23
LY900014
4.
Objectives and Endpoints
Table ITRM.1 shows the objectives and endpoints of the study.  Week 52 endpoints for the 
secondary objectives only apply to the blinded treatment arms of LY900014 and insulin lispro.  
Table ITRM.1.
Objectives and Endpoints
Objectives
Endpoints
Primary Objective
1.
To test the hypothesis that LY900014 is
noninferior to insulin lispro on glycemic
control (NIM=0.4% for HbA1c) in patients 
with T1D, when administered as prandial
insulin (0 to 2 minutes prior to the meal), in
combination with basal insulin glargine or
insulin degludec for 26 weeks
1.
Difference between LY900014 and insulin
lispro in change from baseline to Week 26 in
HbA1c
Multiplicity Adjusted Objectives
2.
To test the hypothesis that LY900014 is
superior to insulin lispro in controlling 1-hour
PPG excursions, when administered as prandial
insulin
2.
Difference between LY900014 and insulin
lispro in the 1-hour PPG excursion (serum
glucose measured 1 hour after the start of the
meal minus fasting serum glucose) from a
MMTT at Week 26
3.
To test the hypothesis that LY900014 is
superior to insulin lispro in controlling 2-hour
PPG excursions, when administered as prandial
insulin
3.
Difference between LY900014 and insulin
lispro in the 2-hour PPG excursion (serum
glucose measured 2 hours after the start of the
meal minus fasting serum glucose) from an
MMTT at Week 26
4.
To test the hypothesis that LY900014 is
superior to insulin lispro on improving
glycemic control (HbA1c) when administered
as prandial insulin
4.
Difference between LY900014 and insulin
lispro in change from baseline to Week 26 in
HbA1c
5.
To test the hypothesis that LY900014
administered as postprandial insulin 20 minutes
after the start of a meal, (LY900014+20), is
noninferior to insulin lispro, administered as
prandial insulin, on glycemic control
(NIM=0.4% for HbA1c)
5.
Difference between LY900014+20 and insulin
lispro in change from baseline to Week 26 in
HbA1c
Other Secondary Objectives
6.
To compare LY900014+20 with insulin lispro
and LY900014 with respect to 1-hour and
2-hour PPG excursions
6.
1- and 2-hour PPG excursions from an MMTT
test at Week 26
7.
To compare the glycemic control of LY900014
with LY900014+20
7.
Change from baseline HbA1c values at
Week 26
8.
To compare LY900014, LY900014+20, and
insulin lispro on the rate of severe
hypoglycemic events
8.
Rate (events/patient/100 years) of severe
hypoglycemic events from baseline through
Week 26 and Week 52

I8B-MC-ITRM Clinical Protocol
Page 24
LY900014
Other Secondary Objectives (continued)
9. To compare LY900014,LY900014+20,and 
insulin lispro with respect to the incidence and 
rate of documented symptomatic postmeal 
hypoglycemia
9. Rate (events/patient/year and/or 
events/patient/30 days) and incidence (percent 
ofpatients with at least 1 event) of documented 
symptomatic postmeal hypoglycemia within 
1and 2 hours after start of a meal from 
Week 12 through Week 26, Week 0 through 
Week 26, Week 26 through Week 52, and 
Week 0 through Week 52
10.To compare LY900014, LY900014+20,and 
insulin lispro with respect to the incidence and 
rate of documented symptomatic hypoglycemia
10.Rate (events/patient/year and/or 
events/patient/30 days) and incidence (percent 
of patients with events) of documented 
symptomatic hypoglycemic events from 
Week 12 through Week 26, Week 0 through 
Week 26, Week 26 through Week 52, and 
Week 0 through Week 52
11.To compare LY900014, LY900014+20, and 
insulin lispro with respect to 1,5-AG 
11.Change from baseline 1,5-AG values at 
Week 26and Week 52
12.To compare LY900014, LY900014+20, and 
insulin lispro with respect to 10-point SMBG
profiles
12.Change from baseline 10-point SMBG values 
at Week 26and Week 52
13.To compare LY900014 , LY900014+20, and 
insulin lispro with respect to total, basal, and 
prandial insulin dose 
13.Change from baseline in total, basal and 
prandial insulin doses and prandial/total insulin 
dose ratiosat Week 26 and Week 52
14.To compare LY900014, LY900014+20, and 
insulin lispro with respect to diabetes treatment 
satisfaction as measured by the ITSQ
14.Change from baseline in ITSQ regimen 
inconvenience and lifestyle flexibility domain 
scores at Week 26and Week 52
15.To compare LY900014, LY900014+20, and 
insulin lispro with respect to the proportion of 
patients achieving HbA1c targets
15.The proportion of patients with HbA1c <7% 
and ≤6.5% at Week 26and Week 52
16.To compare the glycemic control of LY900014 
and insulin lispro
16.Actual and change from baseline to Week 52 in 
HbA1c
Tertiary/ExploratoryObjectives
17.To compare the safety of LY900014, 
LY900014+20, and insulin lispro
17.Adverse events, vital signs, chemistry, and 
hematology laboratory measures
18.To compare the incidenceof treatment-
emergent positive anti-insulin lispro antibodies 
for LY900014, LY900014+20, and insulin 
lispro
18.Incidence of treatment-emergent positive anti-
insulin lispro antibodies
21.To compare LY900014, LY900014+20, and 
insulin lispro with respect to changes in body 
weight
21.Change in weight (kg) from baseline to 
Week 26and Week 52
CCI

I8B-MC-ITRM Clinical Protocol
Page 25
LY900014
Tertiary/Exploratory Objectives (continued)
22.To compare LY900014, LY900014+20, and 
insulin lispro with respect to the proportion of 
patients achieving improvement from baseline 
in HbA1c targets
22.The proportions of patients with shifts in 
HbA1c to <8% and ≤9%, and >9% from 
baseline to Week 26and Week 52
23.To compare LY900014, LY900014 +20, and 
insulin lispro with respect to glycemic
variability 
23.Within-day and between-day glycemic
variability measured by the standard deviation 
andthe coefficient of variation of 10-point 
SMBGprofiles
CCI
Abbreviations: 1,5-AG=1,5-Anhydroglucitol; 
 HbA1c = hemoglobin A1c; ITSQ=Insulin Treatment Satisfaction 
Questionnaire; MMTT=mixed-meal tolerance test; NIM=noninferiority margin; PPG=postprandial glucose;
SMBG= self-monitored blood glucose; T1D = type 1 diabetes mellitus;
 
CCI

I8B-MC-ITRM Clinical Protocol
Page 26
LY900014
5.
Study Design
5.1.
Overall Design
Study I8B-MC-ITRM (ITRM) is a Phase 3, prospective, randomized, outpatient, multinational, 
multicenter, 3-treatment group, parallel, active-controlled study conducted in patients with T1D 
currently using an MDI regimen.  In 2 of the treatment groups, LY900014 and insulin lispro will 
be administered immediately (0-2 minutes) prior to each meal in a double-blind manner.  A third 
open-label treatment group consists of LY900014 administered 20 minutes after the start of a 
meal (LY900014+20). It is not possible to blind this treatment group with different injection 
timing. The study is designed to demonstrate noninferiority of LY900014 when compared with 
insulin lispro in change from baseline to Week 26 in HbA1c, when both are administered at the 
start of the meal.  For patients in the 2 double-blind arms, the study includes a 1-week screening 
period and an 8-week lead-in period followed by a 52-week treatment period and a 4-week safety 
follow-up period. For patients in the open-label treatment group, the treatment period will end 
after 26 weeks, which will be followed by a 4-week safety follow-up period.  
All patients who complete the 4-week safety follow-up visit (Visit 801) and have treatment-
emergent insulin lispro antibodies that have not returned to the prespecified baseline range (Visit 
2) will be asked to participate in follow-up to monitor insulin lispro antibody levels for up to 26
weeks after Visit 801 as described in Appendix 8.
The purpose of the lead-in period (prior to randomization) will be to titrate basal insulin, obtain 
preliminary diagnostic laboratory tests, and determine baseline hypoglycemia rates.  Patients 
treated with insulin glargine U-100 (Basaglar/Abasaglar or LANTUS) once or twice daily, 
insulin glargine U-300 once daily, insulin degludec U-100 or U-200 once daily, insulin detemir 
U-100 once or twice daily, or neutral protamine Hagedorn (NPH) once or twice daily will be 
eligible for inclusion in the trial.  At Visit 2, patients will be switched to an allowed study basal 
insulin regimen; insulin glargine U-100 twice daily, insulin glargine U-100 once daily (either in 
the morning or evening), or insulin degludec U-100 once daily as determined by the investigator. 
The brand of insulin glargine chosen at Visit 2 should remain the same throughout the study; 
switching brands should be avoided. Insulin glargine or insulin degludec will be titrated during 
the 8-week lead-in period using a titration algorithm that should enable patients to reach the 
target fasting blood glucose (FBG) by the end of this period.
All patients using either insulin aspart or insulin glulisine at screening will be transferred to 
insulin lispro at Visit 2 so that all patients are using insulin lispro during the lead-in period.  
Prandial insulin doses or insulin to carbohydrate ratio (ICR), and correction factor (CF) should 
not be changed during the lead-in period except for safety reasons (hypoglycemia or 
unacceptable hyperglycemia) or to facilitate basal insulin optimization.   
At Visit 8, patients will be randomized to either LY900014 at mealtime, insulin lispro at meal-
time, or LY900014 administered 20 minutes after the start of a meal (LY900014+20).  During 
the initial 12 weeks after randomization (intensive titration period), prandial insulin dose should 
be adjusted as necessary in order to meet the target self-monitored blood glucose (SMBG) levels.
Basal insulin may be titrated as needed to facilitate optimal prandial dosing or for safety reasons 

I8B-MC-ITRM Clinical Protocol
Page 27
LY900014
such as hypoglycemia or unacceptable hyperglycemia. Thereafter, during the maintenance 
period (Weeks 12-26 of treatment), it is expected that adjustments to prandial and basal insulin 
doses would be to maintain glycemic control or for safety reasons such as hypoglycemia or 
unacceptable hyperglycemia.
For patients continuing into the 26-week long term maintenance period (2 double-blind arms),
adjustments to both prandial and basal insulins should be made in order to maintain or further 
optimize glycemic control, as appropriate.  
Figure ITRM.1 illustrates the study design.
Abbreviation:  T = telephone visit.
a At Visit 2, patients on insulin glulisine or insulin aspart will be transferred to insulin lispro. The 
patients’ basal insulin regimen will be switched to insulin glargine U-100 (once or twice daily) or to 
insulin degludec U-100 once daily.  At Visit 8, patients will be randomized to either premeal insulin 
lispro, premeal LY900014, or LY900014+20 and continue their basal insulin regimen.
b Titrate basal insulin (see Section 7.2.1.3).
c Titrate prandial insulin (insulin lispro or LY900014) (see Section 7.2.1.4). 
d Patients will discontinue study insulins at Week 26 for the LY900014+20 open-label treatment group 
or Week 52 for the 2 blinded treatment groups.  
e Eligible patients will have visits at approximately 3-month intervals for up to 26 weeks after Visit 801 
for follow-up of insulin lispro antibody levels (see Appendix 8).
Figure ITRM.1.
Illustration of study design for Clinical Protocol I8B-MC-ITRM.

I8B-MC-ITRM Clinical Protocol
Page 28
LY900014
5.2.
Number of Participants
Approximately 1500 participants will be screened to achieve 1199 randomized patients and 
1020 patients completing 26 weeks and approximately 646 patients completing 52 weeks
(double-blind arms only).
5.3.
End of Study Definition
End of the study is the last scheduled procedure shown in the Insulin Lispro Antibody Follow-
Up Assessment Schedule of Activities (Appendix 8) for the last patient.
5.3.1. Safety Follow-Up
Safety follow-up visit guidelines are as follows (see Section 2):

Patients who discontinue from the study early during the lead-in period (prior to 
randomization) should complete an early discontinuation visit only.

Patients who discontinue from investigational product (IP) early but remain in the study 
should complete all remaining visits per Schedule of Activities, including Visit 801.

Patients who discontinue from the study early (regardless of whether they discontinue IP
at the same time or have discontinued IP at an earlier visit) should complete an early 
discontinuation visit followed by the safety follow-up visit (Visit 801) per Schedule of 
Activities.

Patients in the 2 double-blind arms who finish Visit 22 without early discontinuation of 
IP should complete a safety follow-up visit (Visit 801) 4 weeks after Visit 22.

Patients in the open-label treatment group who finish Visit 18 without early 
discontinuation of IP should complete a safety follow-up visit (Visit 801) 4 weeks after 
Visit 18.  
All patients who complete the 4-week safety follow-up visit (Visit 801) and have treatment-
emergent insulin lispro antibodies that have not returned to prespecified baseline range (Visit 2) 
will be asked to participate in follow-up to monitor insulin lispro antibody levels as described in 
Appendix 8.  Patients participating in the antibody follow-up period will complete the study 
when insulin antibodies have returned to baseline range or when Visit 803 is completed, 
whichever occurs first.  
5.4.
Scientific Rationale for Study Design
Study ITRM is a Phase 3 study to evaluate LY900014 compared to insulin lispro each in 
combination with basal insulin in patients with T1D.  The trial has 3 treatment groups, 2 of 
which are double-blind to allow comparison of LY900014 and insulin lispro when injected at the 
start of the meal.  The third treatment group is open-label due to inability to blind postprandial 
injection timing of LY900014 (20 minutes after the start of a meal) and will evaluate the efficacy 
and safety of postprandial dosing.  Patients in the 2 blinded arms will continue with double-blind 
treatment for an additional 26 weeks for a total of 52 weeks to allow comparison of long-term 
safety and efficacy in a blinded manner.  Patients in the open-label treatment group will complete 
their study participation after the 26-week primary endpoint and safety follow-up.

I8B-MC-ITRM Clinical Protocol
Page 29
LY900014
The study is designed to compare HbA1c lowering as the primary endpoint, a measure of 
glycemic control accepted by health care providers and regulatory authorities as a validated 
measure of BG control over time and is the best marker for development and progression of 
diabetes complications.  The lead-in period consists of 8 weeks to allow for optimization of basal 
insulin dosing.  The 26-week treatment period consists of a 12-week intensive titration phase to 
optimize prandial insulin dosing followed by a 14-week maintenance phase, so the primary 
endpoint HbA1c reflects glucose control during the 3-month time period when there are minimal 
changes to insulin dose.  The second 26-week period is a long-term maintenance phase to 
demonstrate durability of glycemic control.  
5.5.
Justification for Dose
LY900014 will have the same insulin lispro concentration (100 U/mL) as that of commercially 
available Humalog.  The addition of treprostinil to the insulin lispro formulation does not modify 
the physical, chemical, or biological integrity of insulin lispro.  The dosage of basal and prandial 
insulins used in this study should be determined based on the individual needs of each patient.  

I8B-MC-ITRM Clinical Protocol
Page 30
LY900014
6.
Study Population
This study will include patients who have been diagnosed with T1D for at least 1 year, using 
insulin continuously for at least 1 year, currently on MDI therapy for at least 90 days, and having
an HbA1c value of ≥7.0 and ≤9.5% at screening.  Patients’ basal insulin may be insulin glargine 
U-100 (Basaglar/Abasaglar or LANTUS) once or twice daily, insulin glargine U-300 once daily, 
insulin degludec U-100 or U-200 once daily, insulin detemir U-100 once or twice daily, or 
neutral protamine Hagedorn (NPH) once or twice daily.  Patients may be on any approved 
injectable rapid-acting insulin analog.
Patients must give written informed consent (approved by Lilly or its designee and the ethical 
review board [ERB] governing the site) before being allowed to participate in the study and 
before any screening assessments are performed. 
Study investigator(s) will review the patient’s records and/or history and screening test 
results/measurements to determine if the patient meets all inclusion and no exclusion criteria to 
qualify for participation in the study.  All screening activities must be completed and reviewed 
before the patient begins the lead-in period.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.
6.1.
Inclusion Criteria
Patients are eligible to be included in the study only if they meet all of the following criteria at 
screening:
Type of Patient and Disease Characteristics
[1]
Men or women diagnosed (clinically) with T1D, based on the World Health 
Organization (WHO) classification (Appendix 5) for at least 1 year prior to 
screening, and continuously using insulin for at least 1 year
Patient Characteristics
[2]
Are at least 18 years of age 
[3]
Have been on MDI therapy including a rapid acting insulin analog (insulin 
lispro U-100, insulin aspart, insulin glulisine) for at least 90 days
[4]
Have been treated for at least 30 days prior to screening with one of the 
following:
a) Insulin glargine U-100 or U-300
b) Insulin detemir U-100
c) Insulin degludec U-100 or U-200
d) NPH
[5]
Have an HbA1c value ≥7.0 and ≤9.5%, according to the central laboratory at 
screening (Visit 1).

I8B-MC-ITRM Clinical Protocol
Page 31
LY900014
[6]
Have a body mass index (BMI) of ≤35.0 kg/m2 at screening (Visit 1).
[7]
Male patients:
a) No male contraception required except in compliance with specific local 
government study
[8]
Female patients:
a) Women not of childbearing potential may participate and include those who 
are:
i)
infertile due to surgical sterilization (hysterectomy, bilateral 
oophorectomy, or tubal ligation), congenital anomaly such as 
Mullerian agenesis; 
Or
ii) postmenopausal – defined as either
(1) a woman 50 to 54 years of age (inclusive) with an intact uterus, not 
on hormone therapy who has had either
(a) cessation of menses for at least 1 year; 
Or
(b) at least 6 months of spontaneous amenorrhea with a follicle-
stimulating hormone >40 mIU/mL; 
Or
(2) a woman 55 or older not on hormone therapy, who has had at least 
6 months of spontaneous amenorrhea; 
Or
(3) a woman at least 55 years of age with a diagnosis of menopause 
prior to starting hormone replacement therapy
b) Women of childbearing potential participating:
i)
Cannot be pregnant or intend to become pregnant
ii) Cannot be breastfeeding (including the use of a breast pump)
iii) Must remain abstinent or use 1 highly effective method of contraception 
or a combination of 2 effective methods of contraception for the entirety 
of the study (See Appendix 7)
iv) Test negative for pregnancy at the time of screening (Visit 1). Note: a 
urine pregnancy test is conducted at Visit 8.  
[9]
Have access to a telephone or alternative means for close monitoring and 
communications, and have access to a reliable cellular signal for transmission of 
the electronic clinical outcomes assessment (eCOA) data

I8B-MC-ITRM Clinical Protocol
Page 32
LY900014
[10] Have refrigeration in the home or have ready access to refrigeration for storage 
of insulin therapy
[11] Patient whom the investigator has determined can be randomized and maintain 
the treatment regimens based on their previous medical history including insulin 
dosing regimens, hypoglycemic episodes, and glycemic control
[12] Capable of, willing, and desirous to do the following:
a) Inject insulin with the use of an insulin injection device (insulin pen) 
according to included directions
b) Perform self-BG monitoring including 10-point SMBG on designated days
(patients using a personal continuous glucose monitoring [CGM] or flash 
glucose monitoring [FGM] device for insulin dosing decisions must still use 
the study glucose meter according to the protocol)
c) Keep records in eCOA as required by this protocol  
d) Participate in two 4-hour mixed-meal tolerance tests (MMTTs) and consume 
a standardized meal for the tests 
e) Follow an algorithm for basal insulin adjustment and individualized prandial 
insulin dosing using fixed pattern adjustment or carbohydrate counting as 
agreed upon with the investigator  
f)
Comply with the use of the study insulin and scheduled visits 
[13] Considered healthy (apart from T1D) upon completion of medical history, 
physical examination, vital signs, electrocardiogram (ECG), and analysis of 
laboratory safety variables, as judged by the investigator
Informed Consent
[14] Have given written informed consent to participate in this study in accordance 
with local regulations.
6.2.
Exclusion Criteria
Patients will be excluded from study enrollment if they meet any of the following criteria at 
screening:
Medical Conditions
[15] Have any other condition (including known drug or alcohol abuse, or 
psychiatric disorder including eating disorder) that precludes the patient from 
following and completing the protocol
[16] Have hypoglycemia unawareness as judged by the investigator
[17] Have had more than 1 episode of severe hypoglycemia (defined as requiring 
assistance due to neurologically disabling hypoglycemia) within the last 
6 months prior to screening

I8B-MC-ITRM Clinical Protocol
Page 33
LY900014
[18] Have had more than 1 emergency room visit or hospitalization due to poor 
glucose control (hyperglycemia or diabetic ketoacidosis) within 6 months prior 
to screening (Visit 1)
[19] Have cardiovascular disease within the last 6 months prior to screening, defined 
as stroke, decompensated heart failure New York Heart Association  class III or 
IV (see Appendix 6), myocardial infarction, unstable angina pectoris, or 
coronary arterial bypass graft
[20] Renal: 
a) History of renal transplantation
b) Currently receiving renal dialysis
c) Serum creatinine >2.0 mg/dL (177 µmol/L) at screening 
[21] Hepatic:  Have obvious clinical signs or symptoms of liver disease (for 
example, acute or chronic hepatitis, or cirrhosis) or elevated liver enzyme 
measurements as indicated below at screening (Visit 1):
a) Total bilirubin level (TBL) ≥2X the upper limit of normal (ULN) (with the 
exception of Gilberts Disease) as defined by the central laboratory,
OR
b) Alanine aminotransferase (ALT) ≥3X ULN as defined by the central 
laboratory
OR
c) Aspartate aminotransferase (AST) ≥3X ULN as defined by the central 
laboratory
[22] Malignancy: Have active or untreated malignancy, have been in remission from 
clinically significant malignancy (other than basal cell or squamous cell skin 
cancer) for less than 5 years, or are at an increased risk for developing cancer or 
a recurrence of cancer in the opinion of the investigator
[23] Have any hypersensitivity or allergy to any of the insulins or excipients used in 
this trial
[24] Have hypersensitivity or allergy to any of the ingredients in the standardized 
test meal (MMTT) (for example, nut allergy)  
[25] Hematologic:  Have had a blood transfusion or severe blood loss within 90 days 
prior to screening or have known hemoglobinopathy, anemia, or any other traits 
known to interfere with measurement of HbA1c
[26] Have presence of clinically significant gastrointestinal disease (for example, 
clinically active gastroparesis associated with wide glucose fluctuations) in the 
investigator’s opinion

I8B-MC-ITRM Clinical Protocol
Page 34
LY900014
[27] Have excessive insulin resistance defined as having received a total daily dose 
of insulin >1.5 U/kg at the time of screening
Prior/Concomitant Therapy
[28] Glucocorticoid therapy:  Receiving chronic (lasting longer than 14 consecutive 
days) systemic glucocorticoid therapy (including IV, intramuscular, SC, or oral, 
but excluding topical, intraocular, intranasal, intra-articular and inhaled 
preparations) or have received such therapy within 8 weeks immediately prior to 
screening (Visit 1) with the exception of replacement therapy for adrenal 
insufficiency
[29] Have been on a treatment regimen that includes regular human insulin or any 
premixed insulins within 90 days prior to screening (Visit 1)
[30] Have used insulin human inhalation powder (Afrezza®) within 90 days prior to 
screening (Visit 1)
[31] Have used CSII within the 90 days prior to screening (Visit 1)
[32] Receiving any oral or injectable medication intended for the treatment of 
diabetes mellitus other than insulins in the 90 days prior to screening (Visit 1)
Prior/Concurrent Clinical Trial Experience
[33] Are currently enrolled in any other clinical trial involving an IP or any other 
type of medical research judged not to be scientifically or medically compatible 
with this study
[34] Have participated, within the last 30 days in a clinical trial involving an IP.  If 
the previous IP has a long half-life, 3 months or 5 half-lives (whichever is 
longer) should have passed
[35] Have previously completed or withdrawn from this study or any other study 
investigating LY900014 after receiving at least 1 dose of the IP
Other Exclusions
[36] Are investigator site personnel directly affiliated with this study and/or their 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally adopted
[37] Are Lilly employees (including employees, temporary contract workers, or 
designees responsible for the conduct of the study)
[38] Are unable and/or unwilling to provide informed consent, to make themselves 
available for the duration of the study, to comply with the use of a data 
collection device to directly record data, or to abide by study procedures
6.3.
Lifestyle Restrictions

Patients should be instructed not to donate blood or blood products during the study. 

I8B-MC-ITRM Clinical Protocol
Page 35
LY900014

Patients should be instructed to avoid major changes in dietary intake or physical 
activity during the 3 days prior to MMTT.  
6.4.
Screen Failures
Individuals who do not meet the criteria for participation in this study (screen failure) may not be 
rescreened.  Retests are also not allowed, except for cases when results are not available from the 
original sample.

I8B-MC-ITRM Clinical Protocol
Page 36
LY900014
7. Treatments
7.1.
Treatments Administered
This study involves a comparison of LY900014 and insulin lispro administered subcutaneously 0
to 2 minutes prior to the start of the meal for 52 weeks.  In a third open-label treatment group, 
LY900014 will be administered postprandially (20 minutes after the start of a meal 
[LY900014+20]) for 26 weeks. Table ITRM.2 shows the treatment regimens.
Table ITRM.2.
Treatment Regimens
Regimen
Dose
Strength
Dose
Administration
Route of
Administration
Timing of 
Administration
LY900014
100 U/mL
Individualized 
dosing
Subcutaneous
0 to 2 minutes before start of the meal
Insulin lispro
100 U/mL
Individualized 
dosing
Subcutaneous
0 to 2 minutes before start of the meal
LY900014+20
100 U/mL
Individualized
dosing
Subcutaneous
20 minutes after the start of the meal 
The investigator or his/her designee is responsible for the following:

explaining the correct use of the IP to the patient including the importance of
injection site rotation for both basal and prandial insulin

explaining requirements for recording insulin doses and injection times to the
patient

verifying that instructions are followed properly

maintaining accurate records of IP dispensing and collection

at the end of the study, returning all used and unused IP to Lilly, or its designee,
unless the sponsor and sites have agreed all unused medication is to be destroyed
by the site, as allowed by local law
7.1.1. Packaging and Labeling
Clinical trial materials will be labeled as IP as appropriate, and according to the country’s 
regulatory requirements.  Study insulins (LY900014 and insulin lispro) will be supplied by Lilly 
or its representative, in accordance with current good manufacturing practices, and will be 
supplied with clinical trial lot numbers.  Instruction for Use for the prefilled devices will be 
provided.
The blinded prefilled pens will contain a concentration of 100 U/mL in 3-mL cartridges of either 
LY900014 or insulin lispro.  The open-label prefilled pens will contain a concentration of 
100 U/mL of LY900014.  

I8B-MC-ITRM Clinical Protocol
Page 37
LY900014
During the lead-in period, 100 U/mL insulin lispro will be provided using open-label prefilled 
pens. 
7.1.2. Medical Devices 
The medical devices provided for use in the study are prefilled pens.  LY900014 prefilled pens 
are new investigational combination products.
7.2.
Method of Treatment Assignment
Patients who meet all criteria for enrollment will be randomized to double-blind or open-label 
treatment at Visit 8.  Assignment to treatment groups will be determined by a computer-
generated random sequence using an interactive web-response system (IWRS).  Patients will be 
randomized to double-blind LY900014, double-blind insulin lispro, or open-label LY900014+20 
in a 4:4:3 ratio.  Stratification will be by country, HbA1c stratum (≤7.5%, >7.5% at Visit 7), type 
of basal insulin during the lead-in period (glargine U-100 or degludec U-100), and prandial 
insulin dosing plan at randomization (carbohydrate counting, pattern adjustment).  
The IWRS will be used to assign all IP during the study, including insulin lispro during the 
lead-in period.  The IWRS will be used to assign prefilled pens containing double-blind IP to 
each patient randomized to the 2 blinded treatment groups and prefilled pens containing open-
label IP to each patient randomized to the LY900014+20 treatment group. Site personnel will 
confirm that they have located the correct prefilled pens by entering a confirmation number 
found on the prefilled pens into the IWRS.
7.2.1. Selection and Timing of Doses
7.2.1.1.
Target Glucose Values for Titration of Insulin Therapy
The overall glycemic control goals for all patients enrolled in the study are similar to those 
recommended by the American Association of Clinical Endocrinologists (AACE) (Bailey et al. 
2016).  Fasting, prandial, postprandial, and bedtime glucose target values used to reach the 
SMBG goals and for determination of titration in insulin therapy are listed in Table ITRM.3.
Table ITRM.3.
Target Glucose Values for Adjustment of Insulin Therapy
Time of Target Blood Glucose Measurement
Self-Monitored Blood Glucose (SMBG) Target (Range)
Fasting or pre morning meal
Target:  100 mg/dL or 5.6 mmol/L
Range:  80 to <110 mg/dL or 4.4 to 6.1 mmol/L
Pre midday meal
Target:  100 mg/dL or 5.6 mmol/L
Range:  80 to <110 mg/dL or 4.4 to 6.1 mmol/L
Pre evening meal
Target:  100 mg/dL or 5.6 mmol/L 
Range:  80 to <110 mg/dL or 4.4 to 6.1 mmol/L
Pre bedtime
Range:  90 to 130 mg/dL or 5.0 to 7.2 mmol/L
1-2 hour postprandial 
Target:  <140 mg/dL or 7.8 mmol/L 

I8B-MC-ITRM Clinical Protocol
Page 38
LY900014
7.2.1.2.
Basal Insulin Therapy
Patients not currently treated with an allowed basal insulin regimen will be transferred at Visit 2 
to an allowed study basal insulin regimen (Section 5.1). The initial basal insulin dose may be 
unit-for-unit of the prestudy basal insulin regimen or 80% of the prior basal insulin daily dose if 
the patient was previously treated with twice daily NPH or insulin glargine U-300.  The basal 
insulin dose may be influenced by other clinical circumstances and safety considerations known 
to the investigator; thus, the prescribed basal insulin dose during the study is determined by, and 
the responsibility of, the investigator.  During the study lead-in period, basal insulin doses should 
be reviewed and adjusted weekly as clinically indicated.
Patients should use the same study basal insulin regimen throughout the trial. The study basal 
insulin can be dosed at any time during the day and should be taken at approximately the same 
time of day throughout the course of the study.  The patient may be transferred from once daily 
to twice daily insulin glargine dosing during the lead-in period if needed to reach the FBG target, 
and should continue the dosing frequency after randomization
7.2.1.3.
Basal Insulin Titration
At all clinic and telephone visits during the 8-week lead-in period, basal insulin dose adjustments 
should be determined by the investigator in discussion with the patient based on SMBG and 
hypoglycemia data.  Additional discussion between visits may be required to enable the patient
to reach the FBG target.  Patients’ basal insulin should be titrated using the titration algorithm to 
reach the FBG target of 100 mg/dL (5.6 mmol/L). For patients using insulin glargine twice daily, 
investigators may also consider use of evening premeal SMBG values for assessment of morning 
insulin glargine dose.
Decreases to the basal insulin dose may be made at any time based upon the judgment of the 
investigator (for example, in response to hypoglycemia). Modifications in the calculation of the 
basal insulin dose may also be influenced by other clinical circumstances and safety 
considerations known to the investigator; thus the prescribed basal insulin dose during the study 
is determined by, and the responsibility of, the investigator.  
Every effort should be made to reach the FBG target during the lead-in period to allow enough 
time for prandial insulin dose adjustments during the titration period; however, basal insulin dose 
may be adjusted if needed to facilitate optimal prandial insulin dosing during the intensive
titration period (Weeks 0 to 12) or for safety reasons.  Thereafter, during the maintenance period
(Weeks 12 to 26), it is expected that adjustments to basal insulin doses would be to maintain 
glycemic control or for safety reasons such as hypoglycemia or unacceptable hyperglycemia. 
Between Weeks 26 and 52, investigators in discussion with patients should titrate prandial 
insulin and/or basal insulin as needed in order to maintain or optimize glycemic control.
Assessments of the basal insulin dose should be made at least at weekly intervals based upon the 
occurrence of hypoglycemia events during the previous week (Table ITRM.4). After the 
hypoglycemia assessment, the median (or middle) FBG value from the 3 previous corresponding 
FBG values can be used for basal insulin adjustment as in Table ITRM.5.  Additional discussion 
between visits may be required to enable the patient to reach the FBG target.  The basal insulin 
dose may be adjusted every 3 to 4 days (twice per week) when appropriate, based on the 

I8B-MC-ITRM Clinical Protocol
Page 39
LY900014
patient’s glycemic needs and SMBG levels.  Investigators may use discretion and provide 
direction for patients to adjust the basal insulin dose.  For patients treated with twice daily insulin 
glargine, the evening premeal SMBG level may be evaluated for assessment of the morning dose 
of insulin glargine.
Table ITRM.4.
Basal Insulin Hypoglycemia Assessment
Hypoglycemic Events in the Previous Week
Basal Insulin Change (units)
2 or more nocturnal hypoglycemia events occur or 1 severe 
hypoglycemia event occurs at any time of the day
Titrate the basal dose down to the previous basal 
insulin dose (or by 10% if this is first dose)
1 nocturnal hypoglycemia event occurs
Do not increase basal insulin dose and consider 
reducing the dose if clinically indicated
No nocturnal events occur
Titrate the basal insulin up based upon the median 
FBG for the previous 3 FBG values.  See 
Table ITRM.5
Abbreviation:  FBG = fasting blood glucose.
Table ITRM.5.
Summary of Basal Insulin Adjustments after Hypoglycemia 
Assessment
When Basal Insulin ≤14 units
When Basal Insulin ≥15 units
If median (middle) FBG
from the 3 previous FBG 
values is:
Adjust the basal dose by:
Adjust the basal dose by:
≤70 mg/dL 
(≤3.9 mmol/L)
Decreasing dose to previous lower dosea
Decreasing dose to previous lower dosea
71–100 mg/dL 
(>3.9–5.6 mmol/L)
No adjustment
No adjustment
101–139 mg/dL 
(>5.6–7.7 mmol/L)
Increasing by 1 unit
Increasing by 2 units
140–179 mg/dL 
(>7.8–9.9 mmol/L)
Increasing by 2 units
Increasing by 3 units
≥180 mg/dL 
(≥10 mmol/L)
Increasing by 3 units
Increasing by 4 units
Abbreviation:  FBG = fasting blood glucose.
a
If there is no previous dose because this was the first assigned dose after randomization, then the basal dose 
should be decreased by 10% in consultation with the investigator.
Source:  Adapted from Bartley et al. 2008 and Bolli et al. 2009.
7.2.1.4.
Study Prandial Insulin Therapy
Patients treated with insulin aspart or insulin glulisine as their prestudy prandial insulin will be 
transferred to insulin lispro (unit for unit) at Visit 2.  Insulin lispro will be dispensed to all 
patients for use throughout the lead-in period.  
Patients will be randomized (Visit 8) to either LY900014 at mealtime, insulin lispro at mealtime, 
or LY900014 administered 20 minutes after the start of a meal (LY900014+20).  Patients will 
administer their first study prandial insulin with the next meal following the baseline MMTT.  

I8B-MC-ITRM Clinical Protocol
Page 40
LY900014
Patients should have 3 doses of prandial insulin per day and eat 3 main meals per day (morning, 
midday, and evening) on a regular basis.  Patients may also eat a snack and cover with bolus 
insulin if that is their usual practice.  
This study will use 2 possible plans for determining prandial insulin dosing including:

Pattern adjustment:  The patient is prescribed a fixed dose or dose range of insulin for 
each meal. The fixed insulin dose may be individualized for each meal.

Carbohydrate counting: The patient performs carbohydrate counting for prandial 
insulin dosing (ICR plan) and prandial insulin dose is based upon the estimated 
carbohydrate content of the meal (as unit insulin per grams carbohydrate).
Carbohydrate counting is the preferred method for determining prandial insulin dosing 
requirements.  For patients entering the study using the pattern adjustment method, education 
and training may be provided at the start of and throughout the 8-week lead-in period to teach 
willing and desirous patients how to effectively use the carbohydrate counting method for 
determining meal time insulin doses.  Patients who have demonstrated proficiency with 
carbohydrate counting in the opinion of the investigator should continue using this method 
during the treatment period.     
The patient should maintain the same prandial insulin dosing plan throughout the study. In order 
to account for potential differences between patients who manage prandial insulin doses using 
pattern adjustment and those who use carbohydrate counting, stratification by patients’ prandial 
insulin dosing plan will ensure balance of this factor across treatments.  Correction factor(s) (for 
example, 1 unit of insulin per glucose [mg/dL or mmol/L] above target goal) may be 
implemented with either prandial insulin dosing plan.  Adjustments in insulin dosage should also 
take into account conditions of stress and/or exercise and should be made individually.
At randomization (Visit 8), the starting study insulin doses may be initiated unit for unit; 
however, investigators may consider reducing the prandial or correction insulin doses by 
approximately 10 to 20% based on the patient’s overall glycemic status or other considerations 
known to the investigator in order to reduce the risk of postprandial hypoglycemia.
For patients who are carbohydrate counting, the insulin to carbohydrate ratio and correction 
factor should be assessed and adjusted as needed, at least weekly, in order to meet the target 
SMBG levels described in Table ITRM.5 during the initial 12 weeks after randomization (the 
intensive titration period). The insulin to carbohydrate ratio may be adjusted every 3 to 4 days 
(twice per week) when appropriate, based on the patient’s glycemic needs and SMBG levels.  
Postprandial SMBG levels from 10-point SMBG profiles should also be evaluated for 
optimization of prandial insulin dosing.  
Additional 2-hour postprandial SMBG monitoring should be considered during the days 
following transition to study insulin beginning at Visit 8.  During the maintenance period, Weeks 
12 to 26 it is expected that prandial insulin dose adjustments would be to maintain glycemic 
control or for safety reasons such as hypoglycemia or unacceptable hyperglycemia; however, if 
SMBG targets have not been achieved, titration of prandial insulin should continue.  Between 

I8B-MC-ITRM Clinical Protocol
Page 41
LY900014
Weeks 26 and 52, investigators in discussion with patients should titrate prandial insulin as 
needed in order to maintain or optimize glycemic control. 
For patients who are using pattern adjustment, the prandial insulin dose should be assessed and 
adjusted as needed 1 to 2 times each week, and the correction factor should be assessed and 
adjusted weekly as needed during the initial 12 weeks after randomization (the intensive titration 
period).  In addition to the weekly investigator dose assessment, investigators may use discretion 
and encourage patients to make 1 additional prandial insulin dose adjustments for a maximum of 
2 prandial adjustments per week. During the maintenance period (Weeks 12-26), prandial 
insulin dose adjustments should be made in order to maintain glycemic control and for safety 
reasons such as hypoglycemia or unacceptable hyperglycemia; however, if glycemic and SMBG 
targets have not been achieved, titration of prandial insulin should continue.  Between Weeks 26 
and 52, investigators in discussion with patients should titrate prandial insulin as needed in order 
to maintain or optimize glycemic control. Modifications in the calculation of the insulin dose 
may also be influenced by other clinical circumstances and safety considerations known to the 
investigator.  Therefore, the prescribed prandial insulin dose is determined by, and the 
responsibility of, the investigator.   
In the pattern adjustment plan, assessment of the prandial insulin dose includes review of the 
previous 3 to 7 days of SMBG levels for the corresponding meal or bedtime (Table ITRM.6).  
For example, if assessing the need to adjust the fasting (pre morning meal) prandial insulin 
dose, review the preceding 3 to 7 pre midday meal SMBG levels. 
Table ITRM.6.
Prandial Insulin Doses and Corresponding Self Monitored Blood 
Glucose Values Pattern Adjustment Plan
Prandial Insulin Dose Assessed
Corresponding SMBG Values for Review
Fasting or morning premeal
3-7 previous midday premeal SMBG values
Midday premeal
3-7 previous evening premeal SMBG values
Evening premeal
3-7 previous bedtime SMBG values
Abbreviation:  SMBG = self-monitored blood glucose.
The median (or middle) value from premeal glucose readings from the 3 to 7 previous days is 
chosen as the “adjustment value” and the change in dose (either increase or decrease) is based 
upon this value (Table ITRM.7). 

I8B-MC-ITRM Clinical Protocol
Page 42
LY900014
Table ITRM.7.
LY900014 or Insulin Lispro Adjustment Algorithm Pattern 
Adjustment Plan
If Meal Time Dose of 
Insulin Lispro is:
Median SMBG Value 
Below Target Range
Median SMBG Value at 
Target Rangea
Median SMBG Value 
Above Target Range
<10 units 
Decrease by 1 unit
No change
Increase by 1 unit
11–19 units 
Decrease by 2 units
No change
Increase by 2 units
>20 units 
Decrease by 3 units
No change
Increase by 3 units
Abbreviation:  SMBG = self-monitored blood glucose.
a
Median SMBG value at target range OR experienced 1 unexplained hypoglycemic event (≤70 mg/dL
[3.9 mmol/L] or signs/symptoms consistent with hypoglycemia noted. 
Target Range: Premeal: 80-130 mg/dL or 4.4-7.2 mmol/L
Bedtime:  90-130 mg/dL or 5.0-7.2 mmol/L.
Source:  Adapted from Bergenstal et al. 2008.
Patients who wear their personal CGM/FGM device prior to study entry will be allowed to 
continue to wear their CGM/FGM device during the study. However, these patients should be 
instructed to perform SMBG monitoring using the study glucose meter according to the protocol.  
Investigators must use the SMBG levels to make treatment decisions.
7.2.1.5.
Transitioning off Study Prandial Insulin Therapy
Patients in the 2 blinded arms should take their last dose of study insulin (LY900014 or insulin 
lispro) at Visit 22 or at early discontinuation.
Patients in the open-label treatment group, LY900014+20, should take their last dose of study 
insulin at Visit 18 with the MMTT or at early discontinuation.   
No special instructions for transition to nonstudy prandial insulin are necessary for patients who 
were randomized to either LY900014 or insulin lispro.  After completion of study treatment 
patients will restart the prandial insulin therapy used prior to study entry.  Additional guidance 
for insulin therapy after the treatment period is provided in Section 7.8.2 and Appendix 8.
7.3.
Blinding
This is a double-blind study in which 2 of the treatment arms, LY900014 and insulin lispro, will 
be administered immediately (0-2 minutes) prior to each meal in a double-blind manner.  
Investigators, patients, and study site personnel will be blinded to assigned dosing regimens 
throughout the study.  A third open-label treatment group consists of LY900014 administered 20 
minutes after the start of a meal (LY900014+20)
To preserve the blinding of the study, the Lilly study team will be blinded to double-blind 
treatment assignments until after the primary endpoint database lock.  A limited number of study 
team members will have access to the unblinded treatment assignments and unblinded data at the 
time of the primary endpoint database lock.  The primary endpoint database lock is planned to 
occur after all patients in the double-blind treatment groups have completed or discontinued the 
study prior to Visit 18 and after all patients in the open-label treatment group have completed 
Visit 801.  Investigators, site staff, clinical monitors, patients, and study team members who 

I8B-MC-ITRM Clinical Protocol
Page 43
LY900014
interact directly with site personnel after primary endpoint database lock will remain blinded to 
the treatment assignments until the study is complete.
Emergency unblinding for AEs may be performed through the IWRS, which may supplement or 
take the place of emergency codes generated by a computer drug-labeling system.  This option 
may be used ONLY if the patient’s well-being requires knowledge of the patient’s treatment 
assignment.  Unblinding events are recorded and reported by the IWRS.
If an investigator, site personnel performing assessments, or patient is unblinded, the patient
must be discontinued from IP and should remain in the study.
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient’s treatment assignment is warranted.  Patient safety must always be the first 
consideration in making such a determination.  If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the Lilly clinical research 
physician (CRP/CRS) prior to unblinding a patient’s treatment assignment unless this could 
delay emergency treatment of the patient.  If a patient’s treatment assignment is unblinded, Lilly 
must be notified immediately.
7.4.
Dosage Modification
See Section 7.2.1.
7.5.
Preparation/Handling/Storage/Accountability
The investigator or his/her designee is responsible for confirming appropriate temperature 
conditions have been maintained during transit for all study treatment received and any 
discrepancies are reported and resolved before use of the study treatment. 
Only patients enrolled in the study may receive IP, and only authorized site staff may supply or 
administer study treatment.  All study treatments should be stored in an environmentally 
controlled and monitored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.
All insulin products must be stored at the investigative site under refrigerated conditions 
(between 2°C and 8°C) in a locked and secure place.  Insulin must not be frozen.
In-use insulins should be maintained at room temperature, and refrigerated material should be 
warmed to near room temperature before injection.  In-use insulin must not be used after 
28 days.
The investigator is responsible for study treatment accountability, reconciliation, and record 
maintenance (such as receipt, reconciliation, and final disposition records).  
7.6.
Treatment Compliance
The investigator or designee will assess compliance of the patient at each visit, based on a review 
of the patient’s glycemic control, adherence to the visit and treatment schedule, and completion 
of patient eCOA.  Patients who are deemed noncompliant will receive additional diabetes 

I8B-MC-ITRM Clinical Protocol
Page 44
LY900014
education and training, as required, and the importance of compliance with the protocol will be 
reinforced.  Patients who, in the opinion of the investigator, are deemed consistently 
noncompliant may be discontinued from IP or from the study.  The prandial insulin dose times 
and meal times will be collected for assessing compliance of the timing of prandial insulin 
administration relative to meal time (premeal and postmeal).
7.7.
Concomitant Therapy
Guidance on restrictions for concomitant therapies is provided in Table ITRM.8.
Table ITRM.8.
Concomitant Medications
Drug Class
Acute 
Use
Chronic 
Use
Safety Follow-Up and 
Insulin Lispro Antibody 
Follow-Up Periods
Conditions
NPH, insulin glargine U-300, 
insulin detemir, insulin 
degludec U-200
No
No
Yes
Regular human insulin
No
No
No
Afrezza(inhaled insulin), or 
premixed human or premixed 
analog insulin
No
No
No
Any noninsulin diabetes 
treatment therapy
No
No
No
Systemic glucocorticosteroid 
(including IV, intramuscular, 
SC, or oral but excluding 
topical, inhaled, intraocular, 
intra-articular, or intranasal 
preparations)
Yes
No
No
During the lead-in period, 
allow 1-time use for 
≤7 consecutive days.  
During all other study 
periods, allow 1-time use for 
≤14 consecutive days.
Abbreviations:  IV = intravenous; NPH = neutral protamine Hagedorn; SC = subcutaneous.
7.8.
Treatment after the End of the Study
7.8.1. Continued Access
LY900014 will not be made available to patients after conclusion of the study.  Rapid-acting 
insulin analogs are available in all countries for use as prandial insulin.    
7.8.2.Special Treatment Considerations
After discontinuation of IP at the end of the treatment period or earlier, randomized patients 
should restart the prandial insulin used prior to study entry.  Patients may remain on the basal 
insulin used during the study (if it was changed at Visit 2) at the discretion of the investigator or 
return to their prestudy basal insulin. Please also refer to Appendix 8 for information regarding 
the insulin lispro antibody follow-up assessment.
Investigators should provide patients with appropriate guidance for glucose monitoring and 
insulin dose adjustment throughout the follow-up period in order to maintain glycemic control.

I8B-MC-ITRM Clinical Protocol
Page 45
LY900014
8.
Discontinuation Criteria
8.1.
Discontinuation from Study Treatment
In the event that a patient is discontinued from the study treatment, the investigator should 
encourage the patient to remain in the study for continued safety monitoring.  
Lilly recognizes the importance of complete data collection.  This study includes elements to 
minimize missing data.  Randomized patients who are discontinued from IP before study 
completion are encouraged to remain in the study for continued monitoring.  For patients who 
remain in the study after early discontinuation of IP, both efficacy (including HbA1c) and safety 
data will be collected at scheduled visits.  The difference between stopping IP and discontinuing 
the study will be explained to patients as part of the informed consent, and patients will be 
encouraged to continue in the study even if they stop study drug.  In addition, study site 
investigators will be trained on the importance of complete data collection, with additional re-
education of sites and patients as necessary.  
8.1.1. Permanent Discontinuation from Study Treatment
Patients will be discontinued from the IP in the following circumstances:

The investigator may decide that the patient should stop IP.  If this decision is
made because of an AE, SAE, or a clinically significant laboratory value, the
study drug is discontinued for that patient and appropriate measures are to be
taken.  Lilly or its designee is to be alerted.

The patient may decide to stop IP.

If the patient becomes pregnant.

If an investigator, study site personnel performing assessments, or patient is
unblinded, the patient must discontinue IP.

If the patient, for any reason, requires treatment with another therapeutic regimen
or therapeutic agent that has been demonstrated to be effective for treatment of
the study indication.  Discontinuation from IP should occur prior to introduction
of the new agent.

Use of prohibited concomitant medication, see Table ITRM.8.

Patient has not taken IP for more than 14 consecutive days.
Discontinuation of the IP for abnormal liver tests should be considered by the investigator when 
a patient meets one of the following conditions after consultation with the Lilly designated 
medical monitor:

ALT or AST >8X ULN.

ALT or AST >5X ULN for more than 2 weeks.

ALT or AST >3X ULN and total bilirubin level(TBL) >2X ULN or prothrombin
time >1.5X ULN.

I8B-MC-ITRM Clinical Protocol
Page 46
LY900014

ALT or AST >3X ULN with the appearance of fatigue, nausea, vomiting, right 
upper-quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).

alkaline phosphatase (ALP) >3X ULN.

ALP >2.5X ULN and TBL >2X ULN.

ALP >2.5 ULN with the appearance of fatigue, nausea, vomiting, right upper-
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
8.1.2. Temporary Discontinuation from Study Treatment
During the study, patients who temporarily discontinue the IP may be able to resume IP based on 
the following scenario.  
Patient has not taken IP for 14 consecutive days or less:

If the treatment regimen restarts within 14 days of when the patient initially stopped 
taking IP, patient may continue in the study and begin treatment again with IP.  
During this time, nonstudy insulins may have been used.  If the patient decides to 
continue in the study, no early termination procedures will be completed.  Patients 
will continue study visits through the safety follow-up.
8.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the sponsor CRP and the investigator to 
determine if the patient may continue in the study.  If both agree it is medically appropriate to 
continue, the investigator must obtain documented approval from the sponsor CRP to allow the 
inadvertently enrolled patient to continue in the study with or without treatment with IP.
8.2.
Discontinuation from the Study
Some possible reasons that may lead to permanent discontinuation include:

Enrollment in any other clinical trial involving an IP or enrollment in any other 
type of medical research judged not to be scientifically or medically compatible 
with this study

Participation in the study needs to be stopped for medical, safety, regulatory, or 
other reasons consistent with applicable laws, regulations, and good clinical 
practice (GCP)

The investigator decides to discontinue the patient from the study

The patient requests to be discontinued from the study

The patient discontinues insulin lispro or study-allowed basal insulin regimen for 
>14 consecutive days in the lead-in period.
Patients who discontinue the study early, but after randomization, will have early discontinuation 
procedures performed as shown in the Schedule of Activities (Section 2).  

I8B-MC-ITRM Clinical Protocol
Page 47
LY900014
Patients who discontinue during the lead-in period will not need to fast, have laboratory tests 
drawn, or complete questionnaires, but will have all other early discontinuation procedures 
performed.
8.3.
Lost to Follow-Up
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site.

I8B-MC-ITRM Clinical Protocol
Page 48
LY900014
9.
Study Assessments and Procedures
Section 2 lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limits for timing).
Appendix 2 lists the laboratory tests that will be performed for this study.
Unless otherwise stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within 60 days of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards.
9.1.
Efficacy Assessments
9.1.1. Primary Efficacy Assessments
The primary efficacy measure is the change from baseline to Week 26 in HbA1c.
9.1.2. Secondary Efficacy Assessments
The following secondary efficacy measures will be collected at the times shown in the Schedule 
of Activities (Section 2).  

Fasting and PPG collected during the MMTT
o
1-hour and 2-hour PPG excursions: serum glucose measured 1 hour and 2 hours
after the start of a meal minus fasting serum glucose
o
Incremental areas under the serum glucose concentration-time curve from 0 to 30
minutes, 0 to 1 hour, 0 to 2 hours, 0 to 3 hours, and 0 to 4 hours after a meal;
maximum serum glucose after a meal
o
Glucose variability measured by the coefficient of variation and standard
deviation (SD)

1,5-Anhydroglucitol (1,5-AG)

SMBG 10-point profiles (fasting, 1 hour post morning meal, 2 hours post morning meal,
pre midday meal, 1 hour post midday meal, 2 hours post midday meal, pre evening meal,
1 hour post evening meal, 2 hours post evening meal, and bedtime)
o
1-hour and 2-hour PPG excursions
o
Within- and between-day glucose variability measured by the coefficient of
variation and SD

Proportion of patients with HbA1c ≤6.5% and <7.0%

Prandial, basal, and total insulin dose (units and units/kg), and prandial/total insulin ratio

I8B-MC-ITRM Clinical Protocol
Page 49
LY900014
9.1.3. Appropriateness of Assessments
All efficacy and safety assessments included in this study are generally regarded as reliable and 
accurate with respect to diabetes mellitus.
9.1.4. Study Procedures
The following procedures will be performed at the times shown in the Schedule of Activities 
(Section 2). 
9.1.4.1.
Electronic Clinical Outcomes Assessment
The eCOA diary will wirelessly receive all glucose data directly from the BG meters, thereby 
increasing the validity of measures reported by the patient and minimizing transcription errors in 
recording the measures.  The use of e-diaries should also allow more complete and accurate 
capturing of hypoglycemia events, as well as more frequent and timely interactions between 
investigator and patients as the intensity of their individual diabetes management increases.  
The system will be used to collect time of the meal and prandial insulin doses (date, time, and 
actual dose taken) and the basal insulin dose, 3 days prior to study visits, on the days of 10-point 
SMBG profiles and at other times as clinically indicated.  For patients who are carbohydrate 
counting, the grams of carbohydrate will be entered for each meal during the 10-point SMBG 
profile days.  Hypoglycemic events will be captured throughout the clinical study in eCOA along 
with date and time of the BG level if measured and hypoglycemia treatment and outcome data.  
Additionally, the eCOA system will incorporate study-specific reminders for patients to perform 
the 10-point SMBG profiles.  
Physicians and designated clinical staff will have access via eCOA portal (secure web-based 
site), to the ongoing near real-time updating of the BG readings, insulin doses administered, 
hypoglycemic events, and dosing time relative to the meal.  Manual inspection of data will 
support at least weekly patient monitoring as an enhancement to standard of care for patient
safety, as well as the potential for reaching an optimum efficacy outcome.  Investigative staff 
will assess clinical data via the eCOA portal and recommend adjustments in basal and prandial 
insulin (also refer to Section 7.2.1). 
An instruction manual will be provided to patients and investigative sites.  Additional instruction 
and training will be provided to the investigative sites regarding data collection, review, retention 
and archival processes.  In the event of eCOA e-diary malfunction or loss, the patient will be 
instructed to immediately contact the investigative site for instructions regarding replacement of 
the equipment. 
9.1.4.2.
Four-Point Self-Monitoring Blood Glucose
Patients should be instructed to measure a minimum of 4 SMBG readings daily (consists of 
fasting [pre morning meal], pre midday meal, pre evening meal, and pre bedtime), with 
additional readings as needed for glucose self-management. Site personnel may request 
additional BG monitoring from patients and/or assess BG values at other times (such as 
postprandial BG measurements) to make clinical management decisions.  Missing values in 4-

I8B-MC-ITRM Clinical Protocol
Page 50
LY900014
point SMBG profiles will not be considered protocol deviations unless, in the opinion of the 
investigator, they are excessive and reflect noncompliance with the protocol.
9.1.4.3.
Ten-Point Self-Monitoring Blood Glucose
Patients in all 3 study arms should be instructed to perform 10-point SMBG profiles prior to 
5 visits during the study (Visits 8, 11, 13, 15, and 18). Patients in the 2 blinded arms will 
perform 10-point SMBG profiles prior to 2 additional visits, Visits 20 and 22. Three 10-point 
profiles should be done during the 2 weeks prior to each visit.  Each 10-point profile during this 
2-week time interval should be completed over a 1-day period, preferably on 3 nonconsecutive 
days (weekdays and weekends) per Section 2.  The 10-point profile consists of 10 SMBG 
measurements on the same day at premeal; 1 hour and 2 hours after the start of the morning, 
midday, and evening meals; and at bedtime.  The 10-point SMBG profile is inclusive of the daily 
4-point SMBG readings.  Patients should be encouraged to eat a morning, midday, and evening 
meal on the days that the 10-point SMBG is monitored.  Premeal measurements should be taken 
before the patient begins eating the meal.  Patients may eat a snack and cover with bolus insulin 
if that is their usual practice.  Missing values in 10-point SMBG profiles will not be considered 
protocol deviations unless, in the opinion of the investigator, they are excessive and reflect 
noncompliance with the protocol.
9.1.4.4.
Mixed-Meal Tolerance Test
A 4-hour MMTT will be performed in all patients at baseline (Week 0, Visit 8) and at the end of 
the 26 weeks of treatment (Visit 18).  Patients will be instructed to fast for at least 8 hours prior 
to the administration of the MMTT at the study site.  
The MMTT can occur 0 to 4 days prior to the visit.  The MMTT can be rescheduled up to 2 
times within the visit window, ideally at 24-hour intervals, if the patient does not meet the target 
FBG.  It is preferred for the rescheduled MMTT to occur as close to the visit date as possible.  
Target FBG prior to the MMTT:  Patients must have an FBG in the range of 71 to 180 mg/dL 
(3.9-10.0 mmol/L) prior to starting the MMTT.  If the glucose is outside of this range, the 
MMTT should be rescheduled.
In order to increase the likelihood of having patients arrive on the morning of the MMTT within 
the target FBG range, please note the following:

Patients should be instructed to avoid major changes in dietary intake or physical activity 
during the 3 days prior to the MMTT.

Patients should be instructed to inject basal insulin according to their usual schedule.

Patients should not administer correction doses with insulin lispro or LY900014 within 4 
hours of the start of the MMTT.
During the 8-hour fasting period and up to 2 hours prior to the start of the MMTT, episodes of 
non-severe hypoglycemia (symptoms or BG ≤70 mg/dL [3.9 mmol/L]) can be treated with 15 to 
20 grams of carbohydrate.  If a hypoglycemic episode requires more than approximately 20 
grams of carbohydrate within 8 hours of the start of the MMTT or the patient experiences a 

I8B-MC-ITRM Clinical Protocol
Page 51
LY900014
severe hypoglycemic episode (as defined in Sections 9.4.1 and 9.4.2), the patient should be
instructed to notify the site and the MMTT must be rescheduled.
Test Meal:  The MMTT meal (approximately 700 kcal and 100 grams of carbohydrate) will 
consist of a liquid nutrition shake(s) (such as Ensure Plus®, Abbott Nutrition).  Patients are 
expected to consume the meal within 15 minutes.  Patients should consume the same test meal 
for both the baseline and end of primary treatment period MMTT, if possible.
Insulin Injection:  During the Visit 8 MMTT, all patients will have insulin lispro injected 
0 to 2 minutes before the start of the meal.  During the Visit 18 MMTT, patients randomized to 
either of the 2 blinded arms will have their blinded study insulin, either LY900014 or insulin 
lispro, injected 0 to 2 minutes before the start of the meal. Patients randomized to the 
LY900014+20 treatment group will have LY900014 injected at 20 minutes after the start of the 
MMTT. The prandial insulin dose administered during the MMTT will be individualized for 
each patient.  

If the patient uses the carbohydrate counting prandial dosing plan, the morning 
meal ICR will be used to calculate the prandial insulin dose for the MMTT.  

If the patient does not use carbohydrate counting, the prandial insulin dose for the 
MMTT should be calculated based on the average total daily insulin dose for the 
3 days prior to the MMTT per Table ITRM.9.

Modifications in the calculation of the insulin dose may also be influenced by 
other clinical circumstances and safety considerations known to the investigator; 
thus the MMTT prandial insulin dose is determined by, and the responsibility of, 
the investigator.    
Table ITRM.9.
Insulin to Carbohydrate Ratio for Determining the Prandial Insulin 
dose for the Mixed-Meal Tolerance Test: For Use with Patients who 
use Pattern Adjustment to Determine Prandial Insulin Doses
Average Total (Basal+Bolus) Insulin Dose 
(units) in the Last 3 Days
Insulin to Carbohydrate Ratio 
(1 unit per number of grams carbohydrate)
8-11 units
1 unit : 50 grams
12-14
1:40 
15-18
1:30 
19-21
1:25 
22-27
1:20 
28-35
1:15 
36-45
1:12 
46-55
1:10 
56-65
1:8 
66-80
1:6 
81-120
1:5 
>120
1:4 
Source: Scheiner [WWW].

I8B-MC-ITRM Clinical Protocol
Page 52
LY900014
Hypoglycemia during the MMTT:  If a patient has signs or symptoms of hypoglycemia during 
the MMTT, BG should be measured with a glucometer.  If the patient’s BG is ≤70 mg/dL 
(3.9 mmol/L), then the patient should receive 15 grams of rapidly absorbable oral carbohydrate.  
The patient’s BG should be retested in 15 minutes or as clinically indicated, and if still ≤70 
mg/dL (3.9 mmol/L), treatment with another 15 grams of carbohydrate should be given until BG 
is >70 mg/dL (3.9 mmol/L).  Sample collection should continue per the schedule if possible.  
Sample Collection:  Time 0 of the MMTT will be when the patient starts to consume the meal.  
Serial venous blood samples to measure serum glucose will be taken at time -15, 0, 15, 30, 60, 
120, 180, and 240 minutes after the start of the meal. 
9.1.4.5.
Diabetes Education and Nutritional Counseling
Initial training at Visit 2 will include diabetes education and nutrition counseling as well as 
hypoglycemia recognition and management.  Appropriate site personnel will administer training 
and education using locally approved diabetes education/training materials and programs or by 
using other materials that may be provided by the sponsor.  Patients may be provided abbreviated 
training and education at visits following Visit 2 based upon patient needs.
9.2.
Adverse Events
Investigators are responsible for monitoring the safety of patients who have entered this study 
and for alerting Lilly or its designee to any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the patient.
The investigator is responsible for the appropriate medical care of patients during the study.
Investigators must document their review of each laboratory safety report.
The investigator remains responsible for following, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the IP or the study, 
or that caused the patient to discontinue the IP before completing the study.  The patient should 
be followed until the event resolves, stabilizes with appropriate diagnostic evaluation, or is 
reasonably explained.  The frequency of follow-up evaluations of the AE is left to the discretion 
of the investigator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the informed consent form (ICF) is signed, study site personnel will record via electronic 
data entry the occurrence and nature of each patient’s preexisting conditions, including clinically 
significant signs and symptoms of the disease under treatment in the study.  In addition, site 
personnel will record any change in the condition(s) and any new conditions as AEs. 
Investigators should record their assessment of the potential relatedness of each AE to protocol 
procedure and/or IP, via electronic data entry.
The investigator will interpret and document whether or not an AE has a reasonable possibility 
of being related to study treatment, study device, or a study procedure, taking into account the 
disease, concomitant treatment, or pathologies.

I8B-MC-ITRM Clinical Protocol
Page 53
LY900014
A “reasonable possibility” means that there is a cause and effect relationship between the IP, 
study device, and/or study procedure and the AE.
The investigator answers yes/no when making this assessment.
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the study.
If a patient’s IP is discontinued as a result of an AE, study site personnel must report this to Lilly 
or its designee via electronic data entry, clarifying if possible, the circumstances leading to any 
dosage modifications or discontinuations of treatment. 
9.2.1. Serious Adverse Events
An SAE is any AE from this study that results in one of the following outcomes:

Death

Initial or prolonged inpatient hospitalization

A life-threatening experience (that is, immediate risk of dying)

Persistent or significant disability/incapacity

Congenital anomaly/birth defect

Considered significant by the investigator for any other reason:  important 
medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious, based upon appropriate medical 
judgment.

When a condition related to the prefilled pen necessitates medical or surgical 
intervention to preclude either permanent impairment of a body function or 
permanent damage to a body structure, the serious outcome of “required 
intervention” will be assigned.

Severe hypoglycemia events: episodes of severe hypoglycemia as determined by 
the investigator according to the definition provided in Sections 9.4.1 and 9.4.2
must be reported as SAEs.
Although all AEs occurring after signing the ICF are recorded in the case report form (CRF), 
SAE reporting begins after the patient has signed the ICF and has received IP.  However, if an 
SAE occurs after signing the ICF, but prior to receiving IP, it needs to be reported ONLY if it is 
considered reasonably possibly related to study procedure.
Study site personnel must alert Lilly or its designee of any SAE within 24 hours of investigator 
awareness of the event via a sponsor-approved method.  If alerts are issued via telephone, they 
are to be immediately followed with official notification on study-specific SAE forms.  This 
24-hour notification requirement refers to the initial SAE information and all follow-up SAE 
information.

I8B-MC-ITRM Clinical Protocol
Page 54
LY900014
Pregnancy (during maternal or paternal exposure to IP) does not meet the definition of an AE.  
However, to fulfill regulatory requirements, any pregnancy should be reported following the 
SAE process to collect data on the outcome for both mother and fetus.
Investigators are not obligated to actively seek AEs or SAEs in patients once they have 
discontinued and/or completed the study (the patient summary CRF has been completed).  
However, if the investigator learns of any SAE, including a death, at any time after a patient has 
been discharged from the study, and the investigator considers the event reasonably possibly 
related to the study treatment or study participation, he/she must promptly notify Lilly.
9.2.1.1.
Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the IB and that the investigator identifies as related to IP or procedure.  United States 21 CFR 
312.32 and European Union Clinical Trial Directive 2001/20/EC and the associated detailed 
guidance or national regulatory requirements in participating countries require the reporting of 
SUSARs.  Lilly has procedures that will be followed for the recording and expedited reporting of 
SUSARs that are consistent with global regulations and the associated detailed guidance.
9.2.2. Complaint Handling
Lilly collects product complaints on IPs and drug delivery systems used in clinical studies in 
order to ensure the safety of study participants, monitor quality, and to facilitate process and 
product improvements.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the IP and/or drug delivery system so that the situation can be 
assessed.

Complaints must be reported by site staff within 24 hours of notification to the clinical 
site/study personnel, or within 24 hours of study/site personnel becoming aware of a 
product issue, regardless of the availability of the complaint sample.  

Retain the IP under appropriate storage conditions, if available or when obtained, until 
instructed to return it to Lilly.  

Product complaints for non-Lilly Products (including concomitant drugs) that do not have 
a Lilly Product Batch or Control number, are reported directly to the manufacturer per 
product label.

Follow the instructions outlined in the Product Complaint Form for other reporting 
requirements.
9.3.
Treatment of Overdose
Excess insulin administration may result in hypoglycemia.  Refer to the IB for LY900014 and 
product label for insulin lispro.  

I8B-MC-ITRM Clinical Protocol
Page 55
LY900014
9.4.
Safety
9.4.1. Hypoglycemia
Patients are encouraged to perform SMBG, whenever hypoglycemia may be suspected, either by 
symptoms experienced or perceived increased risk as related to dietary intake, physical activity, 
or inadvertent or atypical insulin dosing.  All patients will be instructed to treat a BG ≤70 mg/dL 
(3.9 mmol/L) as hypoglycemia.
Hypoglycemia events will be collected in eCOA (see Section 9.1.4.1).  If a hypoglycemia event 
is suspected, the patient should record the BG value, any associated symptoms, and the treatment 
administered in eCOA.  The patient should contact the site as necessary.  Reports of 
hypoglycemia will be classified by the investigator as “severe” or “not severe” based upon data 
collected in eCOA and in consultation with the patient; see below and Section 9.2.1.  All 
episodes of severe hypoglycemia must be reported as AEs via electronic data entry and as SAEs.  
Hypoglycemia will be described using the following definitions:

Documented hypoglycemia:  
o
Documented symptomatic hypoglycemia:  an event during which typical 
symptoms of hypoglycemia are accompanied by BG ≤70 mg/dL (3.9 mmol/L). 
o
Documented asymptomatic hypoglycemia:  an event not accompanied by 
typical symptoms of hypoglycemia but with BG ≤70 mg/dL (3.9 mmol/L). 
o
Documented unspecified hypoglycemia:  an event during which BG ≤70 mg/dL 
(3.9 mmol/L) but no information relative to symptoms of hypoglycemia were
recorded.

Probable symptomatic hypoglycemia:  an event during which symptoms are 
indicative of hypoglycemia and which was presumably caused by BG ≤70 mg/dL
(3.9 mmol/L), although no BG measurement was reported. 

Severe hypoglycemia:  an event requiring assistance of another person to actively 
administer carbohydrate, glucagon, or other resuscitative actions.  During these 
episodes, the patient has an altered mental status and cannot assist in his/her own 
care, may be semiconscious or unconscious, or experience coma with or without 
seizures, and may require parenteral therapy.  BG measurements may not be available 
during such an event, but neurological recovery attributable to the restoration of BG 
concentration to normal is considered sufficient evidence that the event was induced 
by a low BG concentration (BG ≤70 mg/dL [3.9 mmol/L]). 

Nocturnal hypoglycemia:  any hypoglycemic event (documented hypoglycemia or 
probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs 
between bedtime and waking.  

Relative hypoglycemia:  an event during which typical symptoms of hypoglycemia, 
that do not require the assistance of another person, are accompanied by BG 
>70 mg/dL (3.9 mmol/L), but these levels may be quickly approaching the 70 mg/dL 
(3.9 mmol/L) threshold. 

Overall hypoglycemia:  This category combines all cases of hypoglycemia
(documented hypoglycemia and probable symptomatic hypoglycemia, including 

I8B-MC-ITRM Clinical Protocol
Page 56
LY900014
severe hypoglycemia) excluding the events of relative hypoglycemia.  If an event of 
hypoglycemia falls into multiple subcategories, the event is only counted once in this 
category.
9.4.2. Severe Hypoglycemia
The determination of a hypoglycemic event as an episode of severe hypoglycemia as defined 
above, is made by the investigator based upon the medical need of the patient to have required 
assistance and is not predicated on the report of a patient simply having received assistance.
9.4.3. Electrocardiograms
For each patient, ECGs should be performed at Visit 1 according to the study-specific 
requirements described in the Schedule of Activities (Section 2).  
ECGs will be interpreted by a qualified physician (the investigator or qualified designee) at the 
site as soon after the time of ECG collection as possible, and ideally while the patient is still 
present, to determine whether the patient meets entry criteria and for immediate patient
management, should any clinically relevant findings be identified. 
ECGs may be obtained at additional times, when deemed clinically necessary. 
9.4.4. Vital Signs
For each patient, vital sign measurements should be conducted according to the Schedule of 
Activities (Section 2) including the study specific requirements.
9.4.5. Laboratory Tests
For each patient, laboratory tests detailed in Appendix 2 should be conducted according to the 
Schedule of Activities (Section 2 and Appendix 8). 
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient receives the first dose of IP should be reported to Lilly or its designee as an AE
via electronic data entry.
9.4.6. Safety Monitoring
Lilly will periodically review evolving aggregate safety data within the study by appropriate 
methods.
If a study patient experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL 
≥2X ULN, clinical and laboratory monitoring should be initiated by the investigator.  Details for 
hepatic monitoring depend upon the severity and persistence of observed laboratory test 
abnormalities.  To ensure patient/patient safety and comply with regulatory guidance, the 
investigator is to consult with the Lilly CRP regarding collection of specific recommended 
clinical information and follow-up laboratory tests.  See Appendix 4.
9.5.
Pharmacokinetics
Not applicable.

I8B-MC-ITRM Clinical Protocol
Page 57
LY900014
9.6.
Pharmacodynamics
Not applicable.
9.7.
Pharmacogenomics
9.7.1. Whole Blood Samples for Pharmacogenetic Research
A whole blood sample will be collected for pharmacogenetic analysis as specified in the 
Schedule of Activities (Section 2) where local regulations and ERBs allow.  
Samples will not be used to conduct unspecified disease or population genetic research either 
now or in the future.  Samples will be used to investigate variable response to LY900014 and to 
investigate genetic variants thought to play a role in T1D and related complications.  Assessment 
of variable response may include evaluation of AEs or differences in efficacy. 
All pharmacogenetic samples will be coded with the patient number.  These samples and any 
data generated can be linked back to the patient only by the investigator site personnel.  Samples 
will be destroyed according to a process consistent with local regulations.
Samples will be retained for a maximum of 15 years after the last patient visit for the study, or 
for a shorter period if local regulations and/or ERBs/institutional review boards impose shorter 
time limits, at a facility selected by Lilly or its designee.  This retention period enables use of 
new technologies, response to regulatory questions, and investigation of variable response that 
may not be observed until later in the development of LY900014 or after LY900014 becomes 
commercially available.
Molecular technologies are expected to improve during the 15-year storage period and therefore 
cannot be specifically named.  However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, candidate gene studies, and epigenetic analyses.  
Regardless of technology utilized, genotyping data generated will be used only for the specific 
research scope described in this section.
9.8.
Biomarkers and Predictive or Other Analyses
Serum and plasma samples for nonpharmacogenetic biomarker research will be collected at the 
times specified in the Schedule of Activities (Section 2) where local regulations allow.
Biomarker research is performed to address questions of relevance to drug disposition, target 
engagement, pharmacodynamics, mechanism of action, variability of patient response (including 
safety), and clinical outcome.  Sample collection is incorporated into clinical studies to enable 
examination of these questions through measurement of biomolecules including DNA, RNA, 
proteins, lipids, and other cellular elements.
Samples will be used for research on the drug target, disease process, variable response to 
LY900014, pathways associated with T1D, mechanism of action of LY900014, and/or research 
method or in validating diagnostic tools or assay(s) related to T1D. 

I8B-MC-ITRM Clinical Protocol
Page 58
LY900014
All samples will be coded with the patientnumber.  These samples and any data generated can 
be linked back to the patientonly by the investigator site personnel. Samples will be destroyed 
according to a process consistent with local regulations.  
Samples will be retained for a maximum 15 years after the last patientvisit for the study, or for a 
shorter period if local regulations and ERBs impose shorter time limits, at a facility selected by
Lilly or its designee.  This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed untillater 
inthe development of LY900014or after LY900014become(s) commercially available.
9.8.1. Samples for Immunogenicity Testing
Blood samples for immunogenicity testing will be collected to determine antibody production 
against insulin lispro as specified inthe Schedule of Activities (Section 2andAppendix 8). 
Immunogenicity will be assessed by a validated radio ligand-binding assay (RBA) to detect anti-
insulin lispro antibodies in the presence of lispro.  Instead of quantitating the level of anti-insulin 
lispro antibodies by titer, the RBA reports a semiquantitative percent-binding for each positive 
sample.  Additionally, positive samples will be characterized for cross-reactive binding to native 
insulin. 
Clinical and reliable on-market data indicate thatthe immunogenic potential of insulin lispro is 
comparable to other marketed insulins such as regular human insulin (Fineberg et al. 1996) and, 
when present, anti-insulin antibodies do not appear to be clinically consequential (Fineberg et al. 
2003).  Therefore, rather than relying on an in vitro neutralization assay, well established in vivo 
measures of insulin lispro efficacy (that is, insulin dose, HbA1c) will be utilized to directly 
monitor for any potential neutralizing effect of anti-lispro antibodies.
Patients who complete the 4-week safety follow-up visit and have treatment-emergent anti-
insulin lispro antibodiesthat have not returned to prespecified baseline range (Visit 2) will be 
asked to participate in follow-up to monitor antibody levels.  Instructions for this follow-up 
assessmentare provided in Appendix 8. 
Samples will be retained for a maximum of 15 years after the last patientvisitfor the study, or 
for a shorter period if regulations and ERBs impose shorter time limits, at a facility selected by 
Lilly or its designee.  The duration allows the sponsor to respond to future regulatory requests 
related to LY900014.
9.9. Health Economics
The self-reported questionnaires will be administered according to the Schedule of Activities
(Section 2
CCI
)in countries where the questionnaires havebeen translated into the native language of 
the region and linguistically validated.

I8B-MC-ITRM Clinical Protocol
Page 59
LY900014
9.9.2. Insulin Treatment Satisfaction Questionnaire
CCI
The Insulin Treatment Satisfaction Questionnaire (ITSQ) (Anderson et al. 2004) is a validated 
instrument containing 22 items that assesses treatment satisfaction for persons with diabetes on 
CCI
CCI

I8B-MC-ITRM Clinical Protocol
Page 60
CCI
LY900014

I8B-MC-ITRM Clinical Protocol
Page 61
LY900014
10. Statistical Considerations
10.1. Sample Size Determination
Approximately 1199 patients will be randomized in order that 1020 patients complete the study 
through the primary endpoint at Week 26.
The primary objective of this study is to test the hypothesis that LY900014 is noninferior to 
insulin lispro on glycemic control as measured by change from baseline to Week 26 in HbA1c in 
patients with T1D when administered in a double-blind manner as prandial insulin (0-2 minutes 
before meals) in combination with basal insulin.  
Patients will be randomized in a 4:4:3 ratio to double-blind LY900014 dosed 0 to 2 minutes 
before meals, double-blind insulin lispro dosed 0 to 2 minutes before meals, or open-label 
LY900014 dosed 20 minutes after the start of a meal (LY900014+20).  Assuming a 
noninferiority margin (NIM) of 0.4%, no true difference between treatment arms, and an SD of 
1.1%, approximately 371 completers in each double-blind treatment group will provide at least 
99% power to show noninferiority between LY900014 and insulin lispro in change from baseline 
to 26 weeks in HbA1c using the upper limit of a 2-sided 95% confidence interval (CI) 
(LY900014 – insulin lispro).  Assuming a 15% dropout rate for 26 weeks, approximately 1199
patients (436 in each double-blind treatment group and 327 in the open-label treatment group) 
will need to be randomized.  This sample size also has 95% power to show noninferiority 
between LY900014 and insulin lispro using a 0.3% NIM at 26 weeks.  
10.2. Populations for Analyses
For purposes of analysis, the following populations are defined:
Population
Description
Entered
All patients who give informed consent.
Enrolled
All patients who receive at least 1 dose of open-label insulin lispro in the 8-week lead-in period.
Randomized
All patients who are randomly assigned to study treatment at Visit 8.  Treatment group will be 
defined on the basis of the treatment the patients are assigned.
Safety
All randomized patients who receive at least 1 dose of the randomly assigned IP.
Completer
Patients included in the randomized population who have completed Week 26 of study treatment 
without permanent discontinuation of IP.  
Per Protocol
Patients included in the randomized population who have completed Week 26 of study treatment 
without permanent discontinuation of IP and without significant protocol deviations through 
Week 26 that would significantly impact the primary objective.  
Treatment group will be defined on the basis of the treatment the patients actually receive.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis of this study will be the responsibility of Lilly or its designee.  Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 

I8B-MC-ITRM Clinical Protocol
Page 62
LY900014
changes a principal feature of the protocol.  Any other change to the data analysis methods 
described in the protocol, and the justification for making the change, will be described in the 
statistical analysis plan (SAP) or the clinical study report (CSR).  Additional exploratory 
analyses of data will be conducted, as deemed appropriate.
The primary analysis is for the treatment period through Week 26. The primary endpoint is the 
HbA1c measurement obtained at Week 26 (Visit 18).  The measurement obtained at Week 52 
(Visit 22) will be a secondary endpoint.  
Efficacy analyses will be conducted on all randomized patients according to the treatment the 
patients are assigned.  The analyses for the primary and multiplicity adjusted objectives will be 
performed for the efficacy estimand including data collected prior to permanent discontinuation 
of IP through Week 26 and for the ITT estimand (treatment regimen estimand) including all data 
collected through Week 26 regardless of IP use (Section 10.3.3.1). Unless otherwise specified, 
the efficacy analyses for other secondary objectives and exploratory objectives will be performed 
for the efficacy estimand. When change from baseline is included as a response variable of 
analysis models, the patient will be included in the analysis only if he/she has a baseline and a 
postbaseline measurement.  Selected efficacy analyses will also be conducted using the Per-
Protocol (PP) and Completer populations.  Week 52 analyses will include the LY900014 and 
insulin lispro treatment and only be performed for the efficacy estimand.  
Safety analyses will be conducted on the Safety population. Analyses of AEs will include 2 sets 
of analyses, unless otherwise specified.  The first set of analyses will include data collected prior 
to permanent discontinuation of IP.  The second set of analyses will include all data collected 
during the course of the entire study regardless of IP use. Analyses of hypoglycemia will be 
conducted on data collected prior to permanent discontinuation of IP, while analyses for post-
treatment may be conducted as needed. Analyses of safety laboratory measurements will be 
performed on all data collected during the planned treatment period regardless of IP use. Week 
26 analyses will include treatment comparisons among the three treatment groups. Week 52 
analyses will also include data collected during the follow-up visit for LY900014 and insulin 
lispro.  All data collected including the follow-up visit will be summarized for LY900014+20. 
Unless otherwise noted, all tests of treatment effects will be conducted at a 2-sided alpha level of 
0.05, and CIs will be calculated at 95%, 2-sided.  All tests of interactions between treatment 
groups and other factors will be conducted at a 2-sided alpha level of 0.10.  Countries in similar 
geographic regions with fewer than 10 patients, based on the all-randomized population, will be 
pooled to achieve a pooled country of at least 10 patients.  All analyses using country in the 
model will use a pooled country, unless otherwise specified.  The final pooling by country and 
geographic region will be finalized prior to data lock.
A graphical approach for multiple comparisons (Bretz et al. 2011) will be used to strongly 
control the overall Type I error (2-sided alpha level of 0.05) for testing the treatment effect for 
the primary and multiplicity adjusted objectives.  
Baseline is defined as the last nonmissing measurement at or before the randomization visit, 
(Visit 8) unless otherwise specified.  

I8B-MC-ITRM Clinical Protocol
Page 63
LY900014
A restricted maximum likelihood based, mixed-effect model repeated measure (MMRM) 
analysis will be used to analyze continuous longitudinal variables.  All the longitudinal 
observations at each scheduled postbaseline visit will be included in the analysis.  The model for 
the analysis of the primary efficacy endpoint of change from baseline in HbA1c will include the 
fixed class effects of treatment, strata (pooled country, type of basal insulin, and prandial insulin 
dosing plan), visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate 
of baseline value.  For analyses of variables other than HbA1c, the HbA1c stratum (≤7.5%, 
>7.5%) will be included in the model.  An unstructured covariance structure will be used to 
model the within-patient errors.  Significance tests will be based on least squares (LS) means and 
Type III tests.  SAS PROC MIXED will be used to perform the analysis. If this analysis fails to 
converge, the following covariance structures will be tested in order:

Toeplitz with heterogeneity

Autoregressive with heterogeneity

Compound symmetry with heterogeneous variances

Toeplitz

Autoregressive

Compound symmetry without heterogeneous variances.
The first covariance structure that converges will be used.  The Kenward-Roger approximation 
will be used to estimate denominator degrees of freedom.  
Analysis of covariance (ANCOVA) will also be used to analyze continuous variables.  The
model for the change from baseline to the Week 26 HbA1c endpoint will include treatment and
strata (pooled country, type of basal insulin, and prandial insulin dosing plan) as fixed effects 
and baseline as a covariate.  Unless otherwise stated, missing endpoints will be imputed using 
the last-observation–carried-forward (LOCF) approach, using only postbaseline data.  For 
analyses of variables other than HbA1c, the HbA1c stratum (≤7.5%, >7.5%) will be included in 
the model.
For continuous measures, summary statistics will include sample size, mean, SD, median, 
minimum, and maximum for both the actual and the change from baseline measurements.  LS
means and standard errors derived from the analysis models will also be displayed for the change 
from baseline measurements.  Treatment comparisons will be displayed showing the treatment 
difference LS means and the 95% CIs for the treatment differences, along with the p-values for 
the treatment comparisons.
For categorical measures, summary statistics will include sample size, frequency, and 
percentages.  Fisher’s exact test or Pearson’s chi-square test will be used for treatment 
comparisons.

I8B-MC-ITRM Clinical Protocol
Page 64
LY900014
10.3.2. Treatment Group Comparability
10.3.2.1. Patient Disposition
A detailed description of patient disposition will be provided.  Frequency counts and percentages 
of all patients entered, enrolled, randomized, completing, and/or discontinuing from the study 
will be presented for each treatment group.  Reasons for discontinuation from study treatment 
and from the study during the treatment period will be summarized and compared between 
treatment groups using Fisher’s exact tests.  Reasons for discontinuation from the study during 
the lead-in and follow-up periods will be summarized.  
10.3.2.2. Patient Characteristics
Standard baseline characteristics of age, sex, ethnicity, race, height, weight, and BMI will be 
summarized for all randomized patients.  Summary statistics will include sample size, mean, SD, 
median, minimum, and maximum for continuous measures and sample size, frequency, and 
percent for categorical measures.  Comparisons between treatment groups will be performed 
using Fisher’s exact test or Pearson’s chi-square test for categorical data and an analysis of 
variance (ANOVA) with treatment in the model for continuous data.  Baseline diabetes 
characteristics will be summarized in a similar manner.  
Medical history and AEs at baseline will be summarized by preferred term (PT) within system 
organ class (SOC), and comparison between treatment groups will be performed using Fisher’s 
exact test.  
10.3.2.3. Concomitant Therapy
The type of insulin therapy at study entry and at baseline will be compared between treatment 
groups using Fisher’s exact tests.  The dose of basal and bolus insulin therapy during the lead-in 
period will be compared between treatment groups using an ANOVA with treatment in the 
model.  
Concomitant medications used during the treatment period will be summarized and compared 
between treatment groups using Fisher’s exact test.  
10.3.2.4. Treatment Compliance
The proportions of patients compliant with timing of prandial insulin administration relative to 
meal time (premeal and postmeal) will be summarized.  
10.3.3. Efficacy Analyses
10.3.3.1. Primary Analyses
The primary objective of this study is to test the hypothesis that LY900014 is noninferior to 
insulin lispro on glycemic control (NIM=0.4% for HbA1c) in patients with T1D, when 
administered as prandial insulin (0-2 minutes prior to the meal), in combination with basal 
insulin for 26 weeks.  There will be 2 primary analysis methods, each tested at the full 
significance level of 0.05.  
For the US FDA submission, the primary analysis method will use the copy reference approach 
to impute missing data based on multiple imputations with a pattern mixture model.  This 

I8B-MC-ITRM Clinical Protocol
Page 65
LY900014
analysis is for the ITT estimand that will include all data collected from randomization through 
Week 26, regardless of IP use.  The reference will be all observed data from the randomized 
patients in the same treatment group who discontinue IP and complete the study without missing 
data.  After imputation, the primary efficacy comparison will be based on the contrast between 
LY900014 and insulin lispro from the ANCOVA analysis of change from baseline to Week 26 in 
HbA1c using all randomized patients as described in Section 10.3.1.  
If there are only a limited number of patients in the reference group as described above that leads
to a failure in performing the proposed multiple imputation analysis, the reference will be 
changed to include all observed data from all randomized patients in the same treatment arm who 
complete the study without missing data.  
For non-FDA submissions and publications, the primary efficacy comparison will be based on 
the contrast between LY900014 and insulin lispro at Week 26 (Visit 18) from the MMRM 
analysis of change from baseline in HbA1c including data collected from all randomized patients 
prior to permanent discontinuation of IP through Week 26 (efficacy estimand).  The analysis 
model and selection of covariance structure are described in Section 10.3.1.  
For both primary analysis approaches, LY900014 will be declared noninferior to insulin lispro if 
the upper limit of the 2-sided 95% CI for the LS mean difference in the change from baseline in 
HbA1c for LY900014 minus insulin lispro is below +0.4%.  In addition, the 95% CI for the 
treatment difference will be compared to an alternative NIM of +0.3%.  Both estimands will be 
tested at the full significance level of 0.05.  The ANCOVA and MMRM analyses will include 
data from all 3 treatment groups; however, the contrasts between LY900014+20 and insulin 
lispro and between LY900014 and LY900014+20 are not part of the primary efficacy 
comparisons.
In addition to the primary objective, the superiority of LY900014 in controlling HbA1c 
compared to insulin lispro will also be assessed for each analysis approach described above.  If 
the p-value is less than the alpha level from the graphical approach allocated to the superiority 
hypothesis, LY900014 will be declared superior to insulin lispro.
10.3.3.1.1.Sensitivity Analyses for Missing Data
A missing-not-at-random (MNAR)-based analysis will be performed for both the efficacy and 
ITT estimands to assess sensitivity to departures from the missing-at-random (MAR) assumption 
by repeatedly adjusting the imputations of missing data to provide a progressively more severe 
stress test (Ratitch et al. 2013).  The basic idea is to impute the missing values and add a value 
(delta) to the imputed values of the experimental treatment group and perform an analysis for the 
primary endpoint on the delta-adjusted data set to see whether the conclusion of the primary 
analysis is overturned.  If not, a larger delta is chosen and the process repeated until the primary 
result is overturned.  If the delta required to overturn the primary result is not a plausible 
departure from MAR, then the primary result is robust to plausible departures from MAR.  
Imputation under the noninferiority null method (where delta equals the NIM) will be included 
as a special case of the progressive stress test.  

I8B-MC-ITRM Clinical Protocol
Page 66
LY900014
For the ITT estimand, the reference group will be as described for the FDA primary analysis, and 
ANCOVA on the change from baseline to Week 26 in HbA1c will be used.  
For the efficacy estimand, the reference group will be the insulin lispro treatment group.  
Imputation will be for all longitudinal visits   
10.3.3.1.2.Additional Analyses for the Primary Endpoint
The primary MMRM analysis model will be repeated using the PP and Completer populations to 
check the sensitivity of the analysis.  If the conclusion differs from that of all randomized 
patients, the data and analyses will be further investigated.  
A secondary analysis model for the efficacy estimand will be an ANCOVA for HbA1c change 
from baseline to Week 26 (Visit 18), using the model described in Section 10.3.1. Missing 
endpoints will be imputed using the LOCF approach using postbaseline data only.  
10.3.3.2. Secondary Analyses
A graphical approach for multiple comparisons will be used to strongly control the overall 
Type I error (2-sided alpha level of 0.05) for testing the treatment effect for the primary and the 
following multiplicity adjusted objectives:  superiority of LY900014 compared with insulin 
lispro for 1-hour PPG excursion at Week 26, 2-hour PPG excursion at Week 26, and change 
from baseline to Week 26 in HbA1c; and noninferiority of LY900014+20 to insulin lispro in 
change from baseline to Week 26 in HbA1c.  Analyses will be performed for both the efficacy 
estimand and ITT estimand as described in Section 10.3.3.1 using the same graphical testing 
scheme.
The graphical testing scheme will be described in the SAP.  The study total alpha level (or 
study-wise type I error) is preset to be 5% for each estimand. The study total alpha level will be 
used for the primary objective in the initial step. The alpha level will be allocated to other key 
endpoints based on the weights in testing paths once the primary endpoint is successfully 
demonstrated. If 1 of the remaining hypotheses is successfully demonstrated with the preserved 
alpha level, its preserved alpha will be allocated to the remainder of the hypotheses by the 
weights in the paths. The iterative test procedure continues until none of the remaining 
hypotheses can be demonstrated with their preserved alphas or all hypotheses are demonstrated 
successful.
An ANCOVA model with strata (pooled country, type of basal insulin, prandial insulin dosing 
plan, and baseline HbA1c strata [(≤7.5%, >7.5%]) and treatment as fixed effects and baseline as 
a covariate will be used to analyze the 1-hour and 2-hour PPG excursions.  However, if the 
percentage of the patients with missing MMTT data at baseline is higher than 15%, a constrained 
longitudinal data analysis model (Liu et al. 2009; Lu 2010) will be used instead.  Analyses 
details will be documented in the SAP.
Superiority in change from baseline in HbA1c for LY900014 compared with insulin lispro and 
noninferiority in change from baseline in HbA1c for LY900014+20 to insulin lispro will be 
determined from the analysis approaches outlined in Section 10.3.3.1  

I8B-MC-ITRM Clinical Protocol
Page 67
LY900014
HbA1c and change from baseline in HbA1c at all time points will be analyzed by the same 
MMRM model used for the primary analysis for the efficacy estimand.  
Additional continuous secondary efficacy variables, as well as the change from baseline for these 
variables, will be analyzed either by the MMRM or ANCOVA models described in 
Section 10.3.1 for the efficacy estimand.
Treatment comparisons for the proportion of patients with HbA1c <7.0% and ≤6.5% will be 
analyzed using a longitudinal logistic regression with repeated measurements conducted by a 
generalized linear mixed model including independent variables of treatment, baseline HbA1c 
value, visit, baseline HbA1c by visit interaction, and treatment by visit interaction.  An 
unstructured covariance structure will be used.  As a sensitivity analysis, the proportion of 
patients with HbA1c <7.0% and ≤6.5% at Week 26 (Visit 18), imputed using LOCF, will be 
compared using a logistic regression model including treatment and baseline HbA1c value in the 
model.  
Actual and change from baseline in basal, prandial, and total dose, as well as the prandial/total 
insulin dose ratio, will be analyzed by the MMRM models described in Section 10.3.1.
Analyses of efficacy data collected from randomization through Week 52 for comparisons of the 
LY900014 and insulin lispro treatment groups will be similar to those described above for the 
efficacy estimand.  
10.3.3.3. Tertiary/Exploratory Analyses
Continuous variables and the change from baseline for these variables will be analyzed either by 
the MMRM or ANCOVA models described in Section 10.3.1.  Categorical variables will be 
analyzed either by model (for example, logistic regression) or by Fisher’s exact test or Pearson’s 
chi-square test.  Analysis details for the tertiary endpoints will be described in the SAP.
10.3.4. Safety Analyses
Safety measures will include AEs, hypoglycemia, vital signs and weight, treatment exposure, 
laboratory measures, and antibodies to insulin lispro.  Analyses will be performed on data 
collected from randomization through Week 26 for all 3 treatment groups and for data collected 
from randomization through Week 52 for the LY900014 and insulin lispro treatment groups.  
Events that are newly reported after the first dose of IP or reported to worsen in severity from 
baseline will be considered treatment-emergent AEs (TEAEs). The Medical Dictionary for 
Regulatory Activities (MedDRA) lowest level term (LLT) will be used in the treatment-emergent 
assessment.  The maximum severity for each LLT during the baseline period will be used as 
baseline severity.
SAEs, AEs reported as reason for discontinuation from the IP or study, and TEAEs will be 
summarized in tables using the MedDRA PT, sorted by decreasing frequency within the 
LY900014 treatment group.  TEAEs will also be summarized by PT sorted by decreasing 
frequency within SOC for all TEAEs and by maximum severity.  For events that are specific to 
only one sex, the denominator and computation of the percentage will include only patients from 

I8B-MC-ITRM Clinical Protocol
Page 68
LY900014
the given sex.  The number and proportion of patients with at least 1 event for each type of event 
will be summarized and compared between treatment groups using Fisher’s exact test.  SAEs, 
AEs reported as reason for discontinuation from the study, and TEAEs will also be summarized 
for open-label insulin lispro during the lead-in period.  
Hypoglycemia rates will be summarized for periods of 30 days, 1 year, and 100 years (severe 
hypoglycemia only).  The rate of severe hypoglycemia per 100 years will be compared between 
treatment groups using the empirical method (details will be described in SAP).  For each of the 
other categories of hypoglycemia, thenumber of hypoglycemia events during a specific period 
(rate) after randomization (for example, Weeks 0-12 of treatment period) will be analyzed by 
using a negative binomial regression model.  The model will include treatment and the baseline 
hypoglycemiarate (measured during lead-in) as a covariate.  An offset defined as the log 
transformation of treatment exposure in the specific period (days)/365.25 days (or 30 days) will 
be included in the model to estimate the rate of hypoglycemia per year (or per 30days).  The 
proportion of patients with at least 1 hypoglycemic event in each category (incidence) during a 
specific period after randomization will be analyzed using a logistic regression model including 
treatment and baseline hypoglycemia rate value in the model. 
Continuous safety variables, as well as the change from baseline for these variables, will be 
analyzed by MMRM or ANCOVA models.  For categorical variables, Fisher’s exact test or 
Pearson’s chi-square test will be used to compare treatment groups unless otherwise specified.
The analyses for assessing immunogenicity data will be described in the SAP after being agreed 
with the FDA on the threshold for determining treatment-emergent antibodies to insulin lispro.
10.3.5.Other Analyses
For the ITSQ, the change from baseline to LOCF endpoint while on treatment in each domain 
transformed score (inconvenience, lifestyle, hypoglycemic control, glycemic control, delivery 
system) and overall transformed score will be analyzed using the ANCOVA model described in 
Section 10.3.1
CCI
.
CCI

I8B-MC-ITRM Clinical Protocol
Page 69
LY900014
Analyses of health economics data collected from randomization through Week 52 for 
comparisons of the LY900014 and insulin lispro treatment groups will be similar to those 
described above.  
10.3.5.2. Subgroup Analyses
The following subgroups will be analyzed using the efficacy estimand to evaluate consistency of 
treatment effects on the primary efficacy measure if there are sufficient numbers of patients in 
each treatment by subgroup (for example, 10%):
•
Age (<40 years, ≥40 years)
•
HbA1c stratum (≤7.5%, >7.5%)
•
Type of basal insulin during the lead-in period (glargine U-100, degludec U-100)
•
Prandial insulin dosing plan (carbohydrate counting, pattern adjustment)
•
Patient’s personal CGM/FGM use during the study (Yes, No)
•
Sex (male or female)
•
BMI (<25, ≥25 kg/m2 and <30, ≥30 kg/m2)
•
Duration of diabetes (using the median as the cut-off)
•
Race
•
Ethnicity
•
Country
•
Region
•
Baseline 1-hour PPG excursion 
•
Baseline 1-hour PPG (PPG ≤180 mg/dL, >180 mg/dL)
•
Baseline 2-hour PPG excursion 
•
Baseline 2-hour PPG (PPG ≤180 mg/dL, >180 mg/dL)
Analyses for HbA1c and change from baseline in HbA1c will be performed using an MMRM 
model that includes the same fixed effects given for the primary analysis model plus factors of 
subgroup, 2-way interaction of subgroup and treatment, 2-way interaction of subgroup and visit, 
and 3-way interaction of treatment, visit and subgroup.  The interaction of subgroup and 
treatment at the primary endpoint (Week 26) will be evaluated to assess the treatment by 
subgroup interaction.  When analyzing HbA1c stratum (≤7.5%, >7.5%) as a subgroup, the 
baseline HbA1c will be not be included as a covariate to avoid confounding.
Additional subgroup analyses may also be performed.
10.3.6. Interim Analyses
No interim analyses are planned for this study.  If an unplanned interim analysis is deemed 
necessary, the appropriate Lilly medical director, or designee, will be consulted to determine 
whether it is necessary to amend the protocol.
The primary database lock will occur after all patients in the double-blind arms have either 
completed the Week 26 visit or discontinued from the study prior to Week 26, and after all 
patients in the open-label treatment group have completed Visit 801.  Investigators and patients 
will remain blinded to treatment assignments until the final database lock after all patients 

I8B-MC-ITRM Clinical Protocol
Page 70
LY900014
complete the study as described in Section 7.3.  Unblinding details are specified in the 
unblinding plan section of the SAP or a separate unblinding plan document.

I8B-MC-ITRM Clinical Protocol
Page 71
LY900014
11.
References
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its 
complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a 
WHO consultation. Diabet Med. 1998;15(7):539-553.
Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, Balkrishnan R. 
Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther. 
2004;26(4):565-578.
Bailey TS, Grunberger G, Bode BW, Handelsman Y, Hirsch IB, Jovanovič L, Roberts VL,
Rodbard D, Tamborlane WV, Walsh J; American Association of Clinical Endocrinologists 
(AACE); American College of Endocrinology (ACE). American Association of Clinical 
Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring 
consensus statement. Endocr Pract. 2016;22(2):231-261. 
Barrett KE, Barman SM, Boitano S, Brooks HL. Ganong’s review of medical physiology. 25th 
ed. New York: McGraw-Hill Education; 2016. Chapter 24. 
Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir 
compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a 
treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, 
controlled trial. Diabet Med. 2008;25(4):442-449.
Bennett P. Classification and diagnosis of diabetes mellitus and impaired glucose tolerance. In: 
Pickup JC, William G, editors. Textbook of diabetes. Vol. 1. 1st ed. Oxford: Blackwell 
Scientific Publications; 1991:p 37-44.
Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, Rendell M. Adjust 
to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for 
adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31(7):1305-1310.
Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes S, Vitacolonna E, Selam JL, Home PD.
Comparison of a multiple daily insulin injection regime (basal once-daily glargine plus 
mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a 
randomized open parallel multicenter study. Diabetes Care. 2009;32(7):1170-1176. Erratum 
in: Diabetes Care. 2009;32(10):1944.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for 
multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. 
Biom J. 2011;53(6):894-913. 
Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic 
effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients 
previously treated with insulin. Diabetes. 1996;45(12):1750-1754.
Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr. Effect of long-term exposure to 
insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. 
Diabetes Care. 2003;26(1):89-96.

I8B-MC-ITRM Clinical Protocol
Page 72
LY900014
Gan MJ, Albanese-O’Neill A, Haller MJ. Type 1 diabetes: current concepts in epidemiology, 
pathophysiology, clinical care, and research. Curr Probl Pediatr Adolesc Health Care.
2012:42(10):269-291. 
Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.
Humalog [summary of product characteristics]. The Netherlands. Eli Lilly Nederland B.V; 2016.
Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent 
variable in analyses of change from baseline in clinical trials? Stat Med. 2009;28(20):2509-
2530.
Lu K. On efficiency of constrained longitudinal data analysis versus longitudinal analysis of 
covariance. Biometrics. 2010;66(3):891-896.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose 
increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with 
increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-885.
[PMR] Pharmaceutical and healthcare market in CEE and CIS. Remodulin approved in 22 
European countries, also Poland. PMR web site. Available at 
http://www.ceepharma.com/news/25318/remodulin-approved-in-22-european-countries-also-
poland. Published September 1, 2005. Accessed September 16, 2016.
Ratitch B, O’Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to 
statistical analysis using pattern mixture models. Pharm Stat. 2013;12(6):337-347.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and 
activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365.
Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corp; 2014.
Scheiner G. Insulin-to-carb ratios made easy. Available at:
http://integrateddiabetes.com/Articles/insu/carb%20ratio%20article%20for%20mendosa.pdf. 
Published November 2007.  Accessed September 23, 2016.
Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting 
A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 
2013;36(8):2271-2279.
van Reenen M, Janssen B for the EuroQol Research Foundation. EQ-5D-5L User Guide: Basic 
information on how to use the EQ-5D-5L instrument. Available at: 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-
5L_UserGuide_2015.pdf. Accessed December 12, 2016

I8B-MC-ITRM Clinical Protocol
Page 73
LY900014
12.
Appendices

I8B-MC-ITRM Clinical Protocol
Page 74
LY900014
Appendix 1.
Abbreviations and Definitions
Term
Definition
1,5-AG
1,5-Anhydroglucitol
AE
adverse event: Any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship 
with this treatment. An adverse event can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with 
the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
ANOVA
analysis of variance
AST
aspartate aminotransferase
BG
blood glucose
blinding/masking
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the treatment 
but the investigator and/his staff and the patient are not.
A double-blind study is one in which neither the patient nor any of the investigator or sponsor 
staff who are involved in the treatment or clinical evaluation of the patients are aware of the 
treatment received.
BMI
body mass index
CF
correction factor
CGM
continuous glucose monitoring
CI
confidence interval
Product complaint
Product complaints are a customer’s written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a Lilly product after it is released for distribution.
CRP/CRS
clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician, or other medical officer.
CSII
continuous subcutaneous insulin infusion
CSR
clinical study report

I8B-MC-ITRM Clinical Protocol
Page 75
LY900014
ECG
electrocardiogram
eCOA
electronic clinical outcomes assessment
eCRF
electronic case report form
enroll
The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are those 
who have been assigned to a treatment.
enter
Patients entered into a trial are those who sign the informed consent form directly or through 
their legally acceptable representatives.
ERB
ethical review board
FBG
fasting blood glucose 
FDA
FGM
Food and Drug Administration
flash glucose monitoring
GCP
good clinical practice
GD
glucodynamic(s)
GRAS
Generally Recognized As Safe
HbA1c
hemoglobin A1c
IB
Investigator’s Brochure
ICF
informed consent form
ICH
International Conference on Harmonisation
ICR
insulin to carbohydrate ratio
IP
investigational product: A pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical trial, including products already on the market when 
used or assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to gain 
further information about the authorized form.
ITSQ
Insulin Treatment Satisfaction Questionnaire
ITT
intention to treat:  The principle that asserts that the effect of atreatment policy can be best 
assessed by evaluating on the basis of the intention to treat a patient (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the consequence that patients 
allocated to a treatment group should be followed up, assessed, and analyzed as members of 
that group irrespective of their compliance to the planned course of treatment.
IV
CCI
intravenous

I8B-MC-ITRM Clinical Protocol
Page 76
LY900014
IWRS
interactive web-response system
LLT
lowest level term
LOCF
last observation carried forward
LS
least squares
MAR
missing at random
MDI
multiple daily injections
MedDRA
Medical Dictionary for Regulatory Activities
MMRM
mixed-effect model repeated measure
MMTT
mixed-meal tolerance test
NIM
noninferiority margin
NPH
neutral protamine Hagedorn
PK
pharmacokinetic(s)
PP
per protocol
PPG
postprandial glucose
PT
preferred term
RBA
radio ligand-binding assay
SAE
serious adverse event
SAP
statistical analysis plan
SC
Subcutaneous
screen
The act of determining if an individual meets minimum requirements to become part of a pool 
of potential candidates for participation in a clinical study. 
SD
standard deviation
SMBG
self-monitored blood glucose
SOC
system organ class
SUSARs
suspected unexpected serious adverse reactions
T1D
type 1 diabetes

I8B-MC-ITRM Clinical Protocol
Page 77
LY900014
T2D
type 2 diabetes
TBL
total bilirubin level
TEADA
treatment-emergent anti-insulin lispro antibody
TEAE
treatment-emergent adverse event:  An untoward medical occurrence that emerges during a 
defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, which and does not necessarily have to have a causal relationship with this 
treatment.
ULN
upper limit of normal
URI
ultra-rapid insulin
VAS
CCI
visualanalog scale

I8B-MC-ITRM Clinical Protocol
Page 78
LY900014
Appendix 2.
Clinical Laboratory Tests
Clinical Laboratory Testsa
Hematology 
Clinical Chemistry(Serum Concentrations of):
Hemoglobin
Sodium
Hematocrit
Potassium
Erythrocyte count (RBC)
Total bilirubin
Mean cell volume 
Direct bilirubin
Mean cell hemoglobin concentration 
Alkaline phosphatase
Leukocytes (WBC)
Alanine aminotransferase (ALT)
Neutrophils, segmented
Aspartate aminotransferase (AST)
Lymphocytes
Blood urea nitrogen (BUN)
Monocytes
Creatinine
Eosinophils
Uric acid
Basophils
Calcium
Platelets
Chloride
Magnesium
Urinalysis 
Total protein
Specific gravity
Glucose
pH
Albumin
Protein
Creatine kinase (CK)
Glucose
Ketones
Serum glucose, fasting
Blood
1,5 Anhydroglucitol 
Urine leukocyte esterase
HbA1c
Bilirubin 
Nitrite
Lipid Panel 
LDLd
Serology
HDL
Anti-insulin lispro antibodies 
Total cholesterol
Triglycerides
Pregnancy Test (females only)b
Follicle-stimulating hormonec
Stored Samples
Pharmacogenetic samples
Nonpharmacogenetic biomarker samples
Abbreviations:  HDL = high-density lipoproteins; IP = investigational product; LDL = low-density lipoproteins; 
RBC = red blood cells; WBC = white blood cells.
a
All laboratory tests will be assayed by a Lilly-designated central laboratory, unless otherwise noted.
b
Serum pregnancy test must be performed in women of childbearing potential at Visit 1 followed by a urine 
pregnancy test within 24 hours prior to IP exposure at randomization and at other times at the investigator’s 
discretion. When required per local regulations and/or institutional guidelines, local pregnancy testing will occur 
at mandatory times during the study treatment period.  
c
Follicle-stimulating hormone test must be performed at Visit 1 for a postmenopausal woman who is between 
50 and 54 years of age (inclusive) with an intact uterus, not on hormone therapy, and who has had at least 
6 months of spontaneous amenorrhea.
d
This value will be calculated. If triglycerides >400 mg/dL, then direct LDL will be assayed.

I8B-MC-ITRM Clinical Protocol
Page 79
LY900014
Appendix 3.
Study Governance Considerations

I8B-MC-ITRM Clinical Protocol
Page 80
LY900014
Appendix 3.1.
Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Appendix 3.1.1.
Informed Consent
The investigator is responsible for ensuring:

that the patient understands the potential risks and benefits of participating in 
the study

that informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol procedures and prior to the administration of IP.

answering any questions the patient may have throughout the study and 
sharing in a timely manner any new information that may be relevant to the 
patient’s willingness to continue his or her participation in the trial.
Appendix 3.1.2.
Ethical Review
The investigator or an appropriate local representative must give assurance that the ERB was 
properly constituted and convened as required by International Conference on Harmonisation 
(ICH) guidelines and other applicable laws and regulations.
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigative site(s).  Lilly or its representatives must approve the ICF, 
including any changes made by the ERBs, before it is used at the investigative site(s).  All ICFs 
must be compliant with the ICH guideline on GCP.
The study site’s ERB(s) should be provided with the following:

the current IB and updates during the course of the study

ICF

relevant curricula vitae.
Appendix 3.1.3.
Regulatory Considerations
This study will be conducted in accordance with:

consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council for International Organizations of
Medical Sciences (CIOMS) International Ethical Guidelines

applicable ICH GCP Guidelines

applicable laws and regulations
Some of the obligations of the sponsor will be assigned to a third-party.

I8B-MC-ITRM Clinical Protocol
Page 81
LY900014
Appendix 3.1.4.
Investigator Information
Physicians with a specialty in endocrinology or primary care physicians specializing in 
endocrinology or internal medicine will participate as investigators in this clinical trial.
Appendix 3.1.5.
Protocol Signatures
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study.
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative.
Appendix 3.1.6.
Final Report Signature
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study.
An investigator will be selected by the Lilly study team to serve as the CSR coordinating 
investigator. The sponsor’s responsible medical officer and statistician will approve the final 
CSR for this study, confirming that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study.
Appendix 3.2.
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:

provide instructional material to the study sites, as appropriate

sponsor start-up training to instruct the investigators and study coordinators.  This 
training will give instruction on the protocol, the completion of the case report 
forms (CRFs), and study procedures.

make periodic visits to the study site

be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax

review and evaluate CRF data and use standard computer edits to detect errors in 
data collection

conduct a quality review of the database.
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study site.  The study may be audited by Lilly or its 
representatives, and/or regulatory agencies at any time.  Investigators will be given notice before 
an audit occurs.
The investigator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the investigator will provide the sponsor, 

I8B-MC-ITRM Clinical Protocol
Page 82
LY900014
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents.
Appendix 3.2.1.
Data Capture System
An electronic data capture system will be used in this study.  The site maintains a separate source 
for the data entered by the site into the sponsor-provided electronic data capture system.
Electronic clinical outcomes assessment (eCOA) measures (for example, a rating scale) or other 
data reported directly by the patient (for example, daily dosing schedule, event diary) are entered 
into an eCOA instrument (for example, personal digital assistant) at the time that the information 
is obtained.  In these instances where there is no prior written or electronic source data at the site, 
the eCOA instrument record will serve as the source.
If eCOA records are stored at a third party site, investigator sites will have continuous access to 
the source documents during the study and will receive an archival copy at the end of the study 
for retention.
Any data for which the eCOA instrument record will serve to collect source data will be 
identified and documented by each site in that site’s study file.
CRF data will be encoded and stored in a clinical trial database.  Data managed by a central 
vendor, such as laboratory test data, will be stored electronically in the central vendor’s database 
system.  Data will subsequently be transferred from the central vendor to the Lilly data 
warehouse.
Data from complaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management system.
Appendix 3.3.
Study and Site Closure
Appendix 3.3.1.
Discontinuation of Study Sites
Study site participation may be discontinued if Lilly, the investigator, or the ERB of the study 
site judges it necessary for medical, safety, regulatory, or other reasons consistent with 
applicable laws, regulations, and GCP.
Appendix 3.3.2.
Discontinuation of the Study
The study will be discontinued if Lilly judges it necessary for medical, safety, regulatory, or 
other reasons consistent with applicable laws, regulations, and GCP.

I8B-MC-ITRM Clinical Protocol
Page 83
LY900014
Appendix 4.
Hepatic Monitoring Tests for Treatment-
Emergent Abnormality
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may 
be required in follow-up with patients in consultation with the Lilly, or its designee, clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hematologya
Haptoglobina
Hemoglobin
Hematocrit
Hepatic Coagulationa
RBC
Prothrombin time
WBC
Prothrombin time, INR
Neutrophils, segmented
Lymphocytes
Hepatic Serologiesa,b
Monocytes
Hepatitis A antibody, total
Eosinophils
Hepatitis A antibody, IgM
Basophils
Hepatitis B surface antigen
Platelets
Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistrya
Hepatitis C antibody
Total bilirubin
Hepatitis E antibody, IgG
Direct bilirubin
Hepatitis E antibody, IgM
Alkaline phosphatase
ALT
Anti-nuclear antibodya
AST
GGT
Alkaline phosphatase isoenzymesa
CPK
Anti-smooth muscle antibody (or anti-actin antibody)a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma-glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cells; WBC = white blood cells.
a
Assayed by Lilly-designated or local laboratory (if test results are required urgently to manage patient care).
b
Reflex/confirmation dependent on regulatory requirements and/or testing availability.

I8B-MC-ITRM Clinical Protocol
Page 84
CCI
LY900014

I8B-MC-ITRM Clinical Protocol
Page 85
LY900014
Appendix 6.
New York Heart Association Cardiac 
Disease Classification
Functional Capacity
Class I
Patients with cardiac disease but without resulting limitation of physical activity.  Ordinary 
physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.
Class II
Patients with cardiac disease resulting in slight limitation of physical activity.  They are 
comfortable at rest.  Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal 
pain.
Class III
Patients with cardiac disease resulting in marked limitation of physical activity.  They are 
comfortable at rest.  Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal 
pain.
Class IV
Patients with cardiac disease resulting in inability to carry on any physical activity without 
discomfort.  Symptoms of heart failure or the anginal syndrome may be present even at rest.  If 
any physical activity is undertaken, discomfort increases.
1994 Revisions to Classification of Functional Capacity and Objective Assessment of Patients 
with Diseases of the Heart
www.americanheart.org.  ©2011, American Heart Association, Inc.

I8B-MC-ITRM Clinical Protocol
Page 86
LY900014
Appendix 7.
Classification of Contraceptive Methods
Women of childbearing potential must use either 1 highly effective method of contraception or a 
combination of 2 effective methods of contraception.  The patient may choose to use a double-
barrier method of contraception (see chart below).   

Barrier protection methods without concomitant use of a spermicide are not an effective 
or acceptable method of contraception.  Thus, each barrier method must include use of a 
spermicide (that is, condom with spermicide, diaphragm with spermicide, female condom 
with spermicide).  It should be noted, however, that the use of male and female condoms 
as a double-barrier method is not considered acceptable due to the high failure rate when 
these barrier methods are combined.
Methods of Contraception
Highly Effective Methods of Contraception
Effective Methods of Contraception
(must use combination of 2 methods)

Combined oral contraceptive pill and mini-pill

NuvaRing®

Implantable contraceptives

Injectable contraceptives (such as Depo-Provera®)

Intrauterine device (such as Mirena® and ParaGard®)

Contraceptive patch – ONLY women <198 lb or 90 kg

Total abstinence

Vasectomy 

Male condom with spermicide

Female condom with spermicide

Diaphragm with spermicide

Cervical sponge

Cervical cap with spermicide

I8B-MC-ITRM Clinical Protocol
Page 87
LY900014
Appendix 8.
Insulin Lispro Antibody Follow-Up 
Assessment

I8B-MC-ITRM Clinical Protocol
Page 88
LY900014
Rationale for Insulin Lispro Antibody Follow Up Assessment
As requested by the US FDA, any patient who develops a treatment-emergent anti-insulin lispro 
antibody (TEADA) response at any time during the study that has not returned to baseline by the 
completion of Visit 801 should undergo follow-up for antibodies to insulin lispro.  Specific 
thresholds for determining treatment-emergent and return-to-baseline will be specified and 
documented in the SAP after being agreed with the FDA. Data collected during the insulin 
lispro antibody follow-up period is intended to evaluate whether antibodies to insulin lispro
return to the prespecified baseline range and, in cases where antibodies remain elevated, to assess 
the possibility of loss of efficacy that may result from insulin neutralizing antibodies.
Eligibility for Insulin Lispro Antibody Follow-Up Assessment
Any patient who develops a TEADA response that has not returned to the prespecified baseline 
range (based on Visit 2 sample) by the 4-week safety follow-up visit (based on Visit 801 sample) 
will undergo additional insulin lispro antibody monitoring.  Study visits will continue at 
approximately 3-month intervals for a maximum of 6 months (approximately 26 weeks) after 
Visit 801 or until insulin lispro antibodies return to baseline range, whichever occurs sooner.
This follow-up assessment also includes any randomized patient who discontinues study insulin 
treatment prior to the end of the planned treatment period and has a TEADA response that has 
not returned to baseline range by Visit 801.  
At Visit 801, it is recommended that the first insulin lispro antibody follow-up visit (Visit 802) 
be scheduled for all study patients, regardless of TEADA status.  Visit 802 should occur 
approximately 13 weeks after Visit 801..  Insulin lispro antibody percent binding results will not 
be provided to sites. When insulin antibody results are available, to determine whether the 
patient’s insulin antibody levels have returned to baseline range, investigators will be notified 
and Visit 802 can be confirmed or cancelled as appropriate.  
During the insulin lispro antibody follow-up period, investigators will be notified if insulin lispro 
antibodies for a given patient have returned to baseline range, at which time the patient’s 
participation in the follow-up period should be stopped.  In the exceptional circumstance that 
insulin antibody results are not available prior to the next scheduled follow-up visit, patients 
should be instructed to complete the visit as scheduled; however, the blood sample collected as 
part of the visit will only be analyzed if the insulin antibody results from the previous visit are 
still above baseline.
In any case, even where insulin antibodies persist, the insulin lispro antibody follow-up 
assessment is expected to last no longer than 30 weeks from the protocol-scheduled last 
treatment visit.  
Patients should not participate in other clinical trials during the follow-up period. Patients 
entering the protocol as part of a maximized extended enrollment addendum (I8B-MC-ITRM[2])
will not be included in the insulin lispro antibody follow-up assessment.
Procedures for Insulin Lispro Antibody Follow-Up Assessment

I8B-MC-ITRM Clinical Protocol
Page 89
LY900014
In order to reduce potential interference with antibody monitoring during this follow-up period, 
introduction of new insulin formulations should be avoided.  Guidance for diabetes therapy 
during the insulin antibody follow-up period is provided in Section 7.8.2.  
Blood samples for insulin lispro antibody and HbA1c measurements should be collected at 
approximately 3-month intervals for up to 26 weeks after Visit 801.  All SAEs (including severe 
hypoglycemia) and all nonserious AEs should be reported.  Vital signs, body weight, total daily 
prandial insulin dose, total daily basal insulin dose, and information on concomitant medications 
will be collected at each insulin antibody follow-up visit as described in the Insulin Lispro 
Antibody Follow- Up Assessment Schedule of Activities (see chart below).

I8B-MC-ITRM Clinical Protocol
Page 90
LY900014
Schedule of Activities during Insulin Lispro Antibody Follow-Up Assessment
Study Period 
Insulin Lispro Antibody 
Follow-Up Period
ED-IA 
Follow-
Up
eCRF Visit Number
802
803
Visit Window (days)
±14
±14
Time on Study Relative to Last Treatment Dose Visit 
(weeks)
17
30
Time on Study Relative to First Treatment Dose Visit 
(weeks)
Open Label, 43
Double Blind, 
69
56
82
IWRS
X
X
X
Dispense glucose monitoring and ancillary supplies
X
Telephone call for visit reminder or informing patient of 
completion in the study
X
X
Return of unused diabetes medications and study supplies if 
required by local regulations
X
X
X
Concomitant medication 
X
X
X
Total daily prandial insulin dose
X
X
X
Total daily basal insulin dose
X
X
X
Vital signs
X
X
X
Body weight
X
X
X
Adverse events and product complaints
X
X
X
Anti-insulin lispro antibodies 
X
X
Xa
HbA1c
X
X
X
Abbreviations:  eCRF = electronic case report form; ED-IA = early discontinuation-insulin antibody; HbA1c = 
hemoglobin A1c; IWRS = interactive web response system.
a
Insulin lispro antibody samples collected as part of the ED-IA follow-up visit will be analyzed only if the results 
from the previous visit are still above baseline.

I8B-MC-ITRM Clinical Protocol
Page 91
LY900014
Appendix 9.
Clinical Protocol Amendment I8B-MC-
ITRM(a) Summary A Prospective, Randomized, Double-
Blind Comparison of LY900014 to Insulin Lispro with an 
Open-Label Postprandial LY900014 Treatment Group, in 
Combination with Insulin Glargine or Insulin Degludec, 
in Adults with Type 1 Diabetes
PRONTO-T1D
Overview
Protocol I8B-MC-ITRM A Prospective, Randomized, Double-Blind Comparison of LY900014 
to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination 
with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes PRONTO-T1D has 
been amended.  The new protocol is indicated by amendment (a) and will be used to conduct the 
study in place of any preceding version of the protocol.
The overall changes and rationale for the changes made to this protocol are described in the 
following table:

I8B-MC-ITRM Clinical Protocol
Page 92
LY900014
Amendment Summary for Protocol I8B-MC-ITRM Amendment (a)
Section # and Name
Description of Change
Brief Rationale
Several Sections
Removed ‘immediately following the meal, or 
whichever …comes first’  LY900014 +20 arm will 
be 20 minutes after the start of the meal
In response to feedback from the FDA, the timing of postprandial administration 
of LY900014 was specified as 20 minutes after the start of the meal in order to 
ensure that that the timing of the LY900014 +20 arm is clearly differentiated 
from the premeal dosing arm.
Section 1. Synopsis
Updated relevant sections to match main body of 
protocol
Section 2. Schedule 
of Activities
Update to footnote c
Immunogenicity follow up shortened from 1 year to 6 months based on recently 
obtained feedback from the FDA.
Section 5.1. Overall 
Design
Follow up for insulin lispro antibodies reduced from 
48 to 26 weeks
Section 5.2. Number 
of Participants
Increased number of participants and adjusted the 
screened, randomized, and completer numbers 
accordingly
The sample size was increased by 200 patients (100 patients for each of the 
double blind mealtime dosing groups) to increase the statistical power for 
showing superiority in HbA1c reduction between treatments at 26 weeks.  
Section 5.3.1. Safety 
Follow-Up
Changed Visit 805 to Visit 803
Immunogenicity follow up shortened from 1 year to 6 months based on recently 
obtained feedback from the FDA.
Section 6.1. Inclusion 
Criteria
Added flash glucose monitoring (FGM)
FGM is being used more commonly by patients to provide greater insight into 
BG profiles.  Although glucose results are not provided in real time as with CGM 
systems, FGM can provide the patient/investigator with additional information on 
BG profiles that cannot be observed with SMBG alone.  As with patients who use 
their personal CGM during the study, SMBG monitoring requirements using the 
study glucose meter remain the same and investigator insulin dose adjustments 
must be made using results from SMBG monitoring.

I8B-MC-ITRM Clinical Protocol
Page 93
LY900014
Section # and Name
Description of Change
Brief Rationale
Section 7.2. Method 
of Treatment 
Assignment
Replaced stratification by CGM with stratification 
by prandial insulin dosing plan (carbohydrate 
counting, pattern adjustment)
Randomization for study ITRM participants uses 4 stratification factors (country, 
HbA1c, basal insulin use, CGM personal use).  Fewer than 10% of patients are 
expected to use a personal CGM or FGM system during the study.  Because a 
potential imbalance for this factor across treatments in a small number of patients 
will be unlikely to influence primary objective, stratification by CGM/FGM 
personal use was replaced with prandial insulin dosing plan.  For type 1 patients,
carbohydrate counting is the preferred method for optimizing prandial insulin 
dose adjustment and matching insulin with carbohydrate consumption; however, 
pattern adjustment is still the prevailing method for prandial insulin dose 
adjustment used in some of the participating countries in ITRM.  Given the desire 
to make the study applicable for management of T1D in general and to avoid 
mandating use of carbohydrate counting in countries where this is not the usual 
practice, stratification by prandial insulin adjustment method provides the best 
opportunity to ensure equal distribution across treatments.  This resulted in a 
changed from a 1:1:1 randomization ratio to a 4:4:3 randomization ratio.
Section 7.2.1.3. Basal 
Insulin Titration 
Table ITRM.5
Removed footnote a
This footnote was not consistent with the cited references and was duplicative of 
text appearing in the paragraph preceding Table ITRM.4..
Section 7.2.1.4. Study 
Prandial Insulin 
Therapy
Added more details on carbohydrate counting and 
pattern adjustment for prandial insulin dosing. 
Removed stratification by CGM device.
Included the option for patients who currently manage prandial insulin doses 
currently using the pattern adjustment method to receive training and support to 
learn how to use the carbohydrate counting method to determine prandial insulin 
dose requirements beginning at Visit 2, the start of the lead-in period.  
Carbohydrate counting is preferred as it provides the best option to optimize 
prandial insulin dose delivery with planned mealtime carbohydrate consumption.  
Additional guidance for transitioning onto study prandial insulin at the start of 
the randomization period is provided to minimize risk for postprandial 
hypoglycemia.
Section 7.3. Blinding
Added clarification
To make more specific who will remain blinded to study data
Section 7.6.
Treatment 
Compliance
Added IP
To allow patients to continue study if noncompliant

I8B-MC-ITRM Clinical Protocol
Page 94
LY900014
Section # and Name
Description of Change
Brief Rationale
Section 9.1.4.4. 
Mixed-Meal 
Tolerance Test
Added more instruction
To help patients achieve the targeted fasting blood glucose level prior to start of 
the MMTT
Section 10.1. Sample 
Size Determination
Increased sample size and updated numbers of 
randomized and completers
The sample size was increased by 200 patients (100 patients for each of the 
double blind mealtime dosing groups) to increase the statistical power for 
showing superiority in HbA1c reduction between treatments at 26 weeks.  This 
resulted in a changed from a 1:1:1 randomization ratio to a 4:4:3 randomization 
ratio.
Section 10.3.1.
General Statistical 
Considerations
Expanded MMRM description
Replaced strata of patients personal CGM use with 
prandial insulin dosing plan
Per request from the FDA, the primary analysis was modified for the US 
submission to impute missing data and use ANCOVA rather than MMRM.  For 
other purposes, the originally planned MMRM analysis will be used.  The 
changes in these sections reflect updates to the wording related to the primary 
analysis.  
The strata terms in the analysis model were updated to match the changes to the 
stratification factors described above.  
Section 10.3.3.1. 
Primary Analyses
Further explained 2 primary analysis methods; 1 for 
FDA submission, 1 for non-FDA submission and
publication
Section 10.3.3.1.1. 
Sensitivity Analyses 
for Missing Data
Specified ITT estimand and efficacy estimand
Section 10.3.3.1.2. 
Additional Analyses 
for Primary Endpoint
Deleted text
Section 10.3.3.2.
Secondary Analyses
Added more information of graphical testing 
scheme
Replaced strata of patients personal CGM use with 
prandial insulin dosing plan
Section 10.3.5.2. 
Subgroup Analyses
Added subgroup for insulin dosing plan
Added FGM
Section 10.3.6. 
Interim Analyses
Added link to Section 7.3

I8B-MC-ITRM Clinical Protocol
Page 95
LY900014
Section # and Name
Description of Change
Brief Rationale
Appendix 8 Insulin 
Lispro Antibody 
Follow-Up 
Assessment
Reduced time of follow- up to maximum of 6 
months, approximately 26 weeks after Visit 801.  
Removed Visits 804 and 805 from schedule of 
activities and adjusted visit intervals to allow 
antibody follow up visits 802 and 803 to occur at 
approximately 3 month intervals starting from Visit 
801.
Immunogenicity follow up shortened from 1 year to 6 months based on recently 
obtained feedback from the FDA.

I8B-MC-ITRM Clinical Protocol
Page 96
LY900014
Revised Protocol Sections
Note:
Deletions have been identified by strikethroughs.
Additions have been identified by the use of underscore.
1. Synopsis
Objectives/Endpoints
Multiplicity Adjusted Objectives
5. To test the hypothesis that LY900014 administered as postprandial insulin immediately after completion of a meal 
or at 20 minutes after the start of a meal, whichever occurs first (LY900014+20), is noninferior to insulin lispro, 
administered as prandial insulin, on glycemic control (NIM=0.4% for HbA1c)
Treatment Groups and Duration:  
A third open-label treatment group consists of LY900014 administered immediately after completion of a meal or at 
20 minutes after the start of a meal (LY900014+20), whichever occurs first.
Study visits will be scheduled at approximately 3-month intervals for up to 48 26 weeks from Visit 801 or until 
insulin lispro antibodies return to baseline range, whichever occurs sooner.
Number of Patients:
Approximately 1257 1500 participants will be screened to achieve 1005 1199 randomized patients and 
852 1020 patients completing 26 weeks of treatment, with approximately 536 646 patients completing 52 weeks.  
Statistical Analysis:
Efficacy analyses will be conducted on all randomized patients using an intention-to-treat (ITT) approach according 
to the treatment the patients are assigned.  The analyses for the primary and multiplicity adjusted objectives will be 
performed for the efficacy estimand including data collected prior to permanent discontinuation of investigational 
product (IP) through Week 26 and for the ITT estimand (treatment regimen estimand) including all data collected 
through Week 26 regardless of IP use.  
For the US FDA submission, the primary analysis method will use the copy reference approach to impute missing 
data based on multiple imputations with a pattern mixture model.  This analysis is for the ITT estimand that will 
include all data collected from randomization through Week 26, regardless of IP use.  The reference will be all 
observed data from the randomized patients in the same treatment arm who discontinue IP and complete the study 
without missing data.  After imputation, the primary efficacy comparison will be based on the contrast between 
LY900014 and insulin lispro from the ANCOVA analysis of change from baseline to Week 26 in HbA1c using all 
randomized patients.  The model for this analysis will include the fixed class effects of treatment and , strata (pooled 
country, type of basal insulin, and patient’s personal continuous glucose monitoring [CGMprandial insulin dosing 
plan] use during the study), visit, and treatment-by-visit interaction, as well as and the continuous, fixed covariate of 
baseline value.

I8B-MC-ITRM Clinical Protocol
Page 97
LY900014
If there are only a limited number of patients in the reference group as described above that leads to a failure in 
performing the proposed multiple imputation analysis, the reference will be changed to include all observed data 
from all randomized patients in the same treatment arm who complete the study without missing data.  
For non-FDA submissions and publications, the primary efficacy comparison will be based on the contrast between 
LY900014 and insulin lispro at Week 26 (Visit 18) from the MMRM analysis of change from baseline in HbA1c 
including data collected from all randomized patients prior to permanent discontinuation of IP through Week 26 
(efficacy estimand).  The model for this analysis will include the fixed class effects of treatment and strata (pooled 
country, type of basal insulin, and prandial insulin dosing plan), visit, and treatment-by-visit interaction, and the 
continuous, fixed covariate of baseline value. 
For both primary analysis approaches, LY900014 will be declared noninferior to insulin lispro if the upper limit of 
the 2-sided 95% CI for the LS mean difference in the change from baseline in HbA1c for LY900014 minus insulin 
lispro is below +0.4%.  In addition, the 95% CI for the treatment difference will be compared to an alternative NIM 
of +0.3%.  Both estimands will be tested at the full significance level of 0.05.  The ANCOVA and MMRM analyses 
will include data from all 3 treatment groups; however, the contrasts between LY900014+20 and insulin lispro and 
between LY900014 and LY900014+20 are not part of the primary efficacy comparisons.
The primary efficacy comparison will be based on the contrast between LY900014 and insulin lispro at Week 26 
(Visit 18) from the mixed-effect model repeated measure (MMRM) analysis of change from baseline in HbA1c 
using all randomized patients.  If the upper limit of the 2-sided 95% confidence interval (CI) for the least squares 
(LS) mean difference in the change from baseline in HbA1c for LY900014 minus insulin lispro is below +0.4%, 
LY900014 will be declared noninferior to insulin lispro.  In addition, the 95% CI for the treatment difference from 
the MMRM model will be compared to an alternative NIM of +0.3%.    The MMRM analysis will include data from 
all 3 treatment groups; however, the contrasts between LY900014+20 and insulin lispro and between LY900014 and 
LY900014+20 are not part of the primary efficacy comparison.   
A graphical approach (Bretz et al. 2011) for multiple comparisons will be used to strongly control the overall Type I 
error (2-sided alpha level of 0.05) for testing the treatment effect for the primary and the following multiplicity 
adjusted objectives:  superiority of LY900014 compared with insulin lispro for 1-hour PPG excursion at Week 26, 
2-hour PPG excursion at Week 26, and change from baseline to Week 26 in HbA1c; and noninferiority of 
LY900014+20 to insulin lispro in change from baseline to Week 26 in HbA1c.  The same graphical testing scheme 
will be applied for both the efficacy estimand and ITT estimand.
An analysis of covariance (ANCOVA) model with strata (pooled country, type of basal insulin, baseline HbA1c 
strata [(≤7.5%, >7.5%], and patient’s personal CGM useprandial insulin dosing plan during the study), and treatment 
as fixed effects and baseline as a covariate will be used to analyze the 1-hour and 2-hour PPG excursions.  However, 
if the percentage of the patients with missing MMTT data at baseline is higher than 15%, a constrained longitudinal 
data analysis model (Liu et al. 2009; Lu 2010) will be used instead.  Analyses details will be documented in the 
statistical analysis plan (SAP).
2. Schedule of Activities
Footnote c: Visit 802 should occur no sooner thanapproximately 9 13 weeks after Visit 801 to allow time to perform 
antibody testing on the Visit 801 sample.

I8B-MC-ITRM Clinical Protocol
Page 98
LY900014
4. Objectives and Endpoints
Multiplicity Adjusted Objectives
5. To test the hypothesis that LY900014 administered as postprandial insulin immediately after completion of a meal 
or at 20 minutes after the start of a meal, whichever occurs first (LY900014+20), is noninferior to insulin lispro, 
administered as prandial insulin, on glycemic control (NIM=0.4% for HbA1c)
5.1. Overall Design
A third open-label treatment group consists of LY900014 administered immediately after 
completion of a meal or at 20 minutes after the start of a meal (LY900014+20), whichever 
occurs first.
All patients who complete the 4-week safety follow-up visit (Visit 801) and have treatment-
emergent insulin lispro antibodies that have not returned to the prespecified baseline range (Visit 
2) will be asked to participate in follow-up to monitor insulin lispro antibody levels for up to 48 
26 weeks after Visit 801 as described in Appendix 8.
At Visit 8, patients will be randomized to either LY900014 at mealtime, insulin lispro at meal-
time, or LY900014 administered immediately after completion of a meal or at 20 minutes after 
the start of a meal (LY900014+20), whichever occurs first.  
Figure ITRM. 1, footnote e Eligible patients will have visits at approximately 3-month intervals for up to 48 26 weeks 
after Visit 801 for follow-up of insulin lispro antibody levels (see Appendix 8).
5.2. Number of Participants
Approximately 1257 1500 participants will be screened to achieve 1005 1199 randomized 
patients and 852 1020 patients completing 26 weeks and approximately 536 646 patients 
completing 52 weeks (double-blind arms only). 
5.3.1. Safety Follow-Up
Patients participating in the antibody follow-up period will complete the study when insulin 
antibodies have returned to baseline range or when Visit 805 803 is completed, whichever occurs 
first.  
5.4. Scientific Rationale for Study Design
The third treatment group is open-label due to inability to blind postprandial injection timing of 
LY900014 (immediately after completion of a meal or at 20 minutes after the start of a meal, 
whichever occurs first)
6.1 Inclusion Criteria
[12] b) Perform self-BG monitoring including 10-point SMBG on designated days 
(patients using a personal continuous glucose monitoring (CGM) or flash glucose 
monitoring (FGM) device for insulin dosing decisions must still perform the SMBG 
per protocoluse the study glucose meter according to the protocol) 

I8B-MC-ITRM Clinical Protocol
Page 99
LY900014
7.1 Treatments Administered
In a third open-label treatment group, LY900014 will be administered postprandially 
(immediately after completion of the meal or at 20 minutes after the start of a meal, whichever 
occurs first [LY900014+20]) for 26 weeks.
Table ITRM.2.
Treatment Regimens
Regimen
Dose
Strength
Dose
Administration
Route of
Administration
Timing of 
Administration
LY900014+20
100 U/mL
Individualized
dosing
Subcutaneous
20 minutes after the start of the meal 
or immediately after completion of the 
meal, whichever occurs first
7.2. Method of Treatment Assignment
Patients will be randomized to double-blind LY900014, double-blind insulin lispro, or open-
label LY900014+20 in a 4:4:3 ratio.  Stratification will be by country, HbA1c stratum (≤7.5%, 
>7.5% at Visit 7), type of basal insulin during the lead-in period (glargine U-100 or degludec U-
100), and use of patient’s personal CGM systemprandial insulin dosing plan at randomization (-
carbohydrate counting, pattern adjustment during the study (yes/no).
7.2.1.3 Basal Insulin Titration 
Table ITRM.5.
Summary of Basal Insulin Adjustments after Hypoglycemia 
Assessment
When Basal Insulin ≤14 units
When Basal Insulin ≥15 units
If median (middle) FBGa
from the 3 previous FBG 
values is:
Adjust the basal dose by:
Adjust the basal dose by:
≤70 mg/dL 
(≤3.9 mmol/L)
Decreasing dose to previous lower 
dosebdosea
Decreasing dose to previous lower 
dosebdosea
71–100 mg/dL 
(>3.9–5.6 mmol/L)
No adjustment
No adjustment
101–139 mg/dL 
(>5.6–7.7 mmol/L)
Increasing by 1 unit
Increasing by 2 units
140–179 mg/dL 
(>7.8–9.9 mmol/L)
Increasing by 2 units
Increasing by 3 units
≥180 mg/dL 
(≥10 mmol/L)
Increasing by 3 units
Increasing by 4 units
Abbreviation:  FBG = fasting blood glucose.
a
For patients using insulin glargine twice daily, investigators may also consider use of evening premeal SMBG 
values for assessment of morning insulin glargine dose.
ba If there is no previous dose because this was the first assigned dose after randomization, then the basal dose 
should be decreased by 10% in consultation with the investigator.
Source:  Adapted from Bartley et al. 2008 and Bolli et al. 2009.

I8B-MC-ITRM Clinical Protocol
Page 100
LY900014
7.2.1.4. Study Prandial Insulin Therapy
Patients will be randomized (Visit 8) to either LY900014 at mealtime, insulin lispro at mealtime, 
or LY900014 administered immediately after completion of a meal or at 20 minutes after the 
start of a meal (LY900014+20)), whichever occurs first.  
Carbohydrate counting is the preferred method for determining prandial insulin dosing 
requirements.  For patients entering the study using the pattern adjustment method, education 
and training may be provided at the start of and throughout the 8-week lead-in period to teach 
willing and desirous patients how to effectively use the carbohydrate counting method for 
determining meal time insulin doses.  Patients who have demonstrated proficiency with 
carbohydrate counting in the opinion of the investigator should continue using this method 
during the treatment period.     
The patient should maintain the same prandial insulin dosing plan throughout the study.  In order 
to account for potential differences between patients who manage prandial insulin doses using 
pattern adjustment and those who use carbohydrate counting, stratification by patients’ prandial 
insulin dosing plan will ensure balance of this factor across treatments.  Correction factor(s) (for 
example, 1 unit of insulin per glucose [mg/dL or mmol/L] above target goal) may be 
implemented with either prandial insulin dosing plan.  Adjustments in insulin dosage should also 
take into account conditions of stress and/or exercise and should be made individually.
At randomization (Visit 8), the starting study insulin doses may be initiated unit for unit; 
however, investigators may consider reducing the prandial or correction insulin doses 
approximately 10 to-20% based on the patient’s overall glycemic status or other considerations 
known to the investigator in order to reduce risk of postprandial hypoglycemia.
Patients who wear their personal CGM/FGM device prior to study entry will be allowed to 
continue to wear their CGM/FGM device during the study.  However, these patients should be 
instructed to perform SMBG monitoring using the study glucose meter according to the protocol.
In order to account for potential differences between patients who wear a CGM device and those 
who do not, stratification by patients’ personal CGM use will ensure balance of this factor across 
treatments.  Investigators must use the SMBG levels to make treatment decisions.
7.3 Blinding
A third open-label treatment group consists of LY900014 administered 20 minutes after the start 
of a meal (LY900014+20) , whichever occurs first.
Investigators, site staff, clinical monitors, and patients and study team members who interact 
directly with site personnel after primary endpoint database lock will remain blinded to the 
treatment assignments until the study is complete. 
7.6 Treatment Compliance
Patients who, in the opinion of the investigator, are deemed consistently noncompliant may be 
discontinued from IP or from the study.

I8B-MC-ITRM Clinical Protocol
Page 101
LY900014
9.1.4.4. Mixed-Meal Tolerance Test
Patients should have no episodes of hypoglycemia (symptoms or BG ≤70 mg/dL [3.9 mmol/L]) 
during this fasting period.  
Target FBG prior to the MMTT:  Patients must have an FBG in the range of 71 to 180 mg/dL 
(3.9-10.0 mmol/L) prior to starting the MMTT.  If the glucose is outside of this range, the 
MMTT should be rescheduled.
In order to increase the likelihood of having patients arrive on the morning of the MMTT within 
the target FBG range, please note the following:

Patients should be instructed to avoid major changes in dietary intake or physical activity 
during the 3 days prior to the MMTT.

Patients should be instructed to inject basal insulin according to their usual schedule 

Patients should not administer correction doses with insulin lispro or LY900014 within 4 
hours of the start of the MMTT.

During the 8 hour fasting period and up to 2 hours prior to the start of the MMTT, 
episodes of non-severe hypoglycemia (symptoms or BG ≤70 mg/dL [3.9 mmol/L]) can 
be treated with 15 to 20 grams of carbohydrate.  If a hypoglycemia episode requires more 
than approximately 20 grams of carbohydrate within 8 hours of the start of the MMTT or 
the patient experiences a severe hypoglycemia episode (as defined in Sections 9.4.1 and 
9.4.2), the patient should be instructed to notify the site and the MMTT must be 
rescheduled
Insulin Injection:  
Patients should inject basal insulin according to their usual schedule.
10.1. Sample Size Determination
Approximately 1005 1199 patients will be randomized in order that 852 1020 patients complete 
the study through the primary endpoint at Week 26.
Patients will be randomized in a 1:1:14:4:3 ratio to double-blind LY900014 dosed 0 to 2 minutes 
before meals, double-blind insulin lispro dosed 0 to 2 minutes before meals, double-blind insulin 
lispro dosed 0 to 2 minutes before meals, or open-label LY900014 dosed immediately after 
completion of a meal or at 20 minutes after the start of a meal, whichever occurs first
(LY900014+20).  Assuming a noninferiority margin (NIM) of 0.4%, no true difference between 
treatment arms, and an SD of 1.1%, approximately 371 852 completers (284 in each double-
blind treatment group) will provide at least 99% power to show noninferiority between 
LY900014 and insulin lispro in change from baseline to 26 weeks in HbA1c using the upper 
limit of a 2-sided 95% confidence interval (CI) (LY900014 – insulin lispro).  Assuming a 15% 
dropout rate for 26 weeks, approximately 1005 1199 patients (436 in each double-blind treatment 

I8B-MC-ITRM Clinical Protocol
Page 102
LY900014
group and 327 in the open-label treatment group) will need to be randomized.  This sample size 
also has 9095% power to show noninferiority between LY900014 and insulin lispro using a 
0.3% NIM at 26 weeks.  
10.3.1. General Statistical Considerations
Efficacy analyses will be conducted on all randomized patients using an intention-to-treat (ITT)
approach according to the treatment the patients are assigned.  The analyses for the primary and 
multiplicity adjusted objectives will be performed for the efficacy estimand including data 
collected prior to permanent discontinuation of IP through Week 26 and for the ITT estimand
(treatment regimen estimand) including all data collected through Week 26 regardless of IP use 
(Section 10.3.3.1).  
The primary analysis method will be a A restricted maximum likelihood based, mixed-effect 
model repeated measures (MMRM) analysis using will be used to analyze continuous 
longitudinal variables.  Aall the longitudinal observations at each scheduled postbaseline visit
will be included in the analysis.  The model for the analysis of the primary efficacy endpoint of 
change from baseline in HbA1c will include the fixed class effects of treatment, strata (pooled 
country, type of basal insulin, and patient’s personal CGM useprandial insulin dosing plan
during the study), visit, and treatment-by-visit interaction, as well as the continuous, fixed 
covariate of baseline value. 
An Aanalysis of covariance (ANCOVA) will also be used to analyze continuous variables.  The
model for the change from baseline to the Week 26 HbA1c endpoint will include treatment 
andwith strata (pooled country, type of basal insulin, and patient’s personal prandial insulin 
dosing planCGM use during the study), and treatment as fixed effects and baseline as a 
covariate.  will be conducted as supportive analyses.  Unless otherwise stated, mMissing 
endpoints will be imputed using the last-observation–carried-forward (LOCF) approach, using 
only postbaseline data.  For analyses of variables other than HbA1c, the HbA1c stratum (≤7.5%, 
>7.5%) will be included in the model.
10.3.3.1. Primary Analyses
The primary objective of this study is to test the hypothesis that LY900014 is noninferior to 
insulin lispro on glycemic control (NIM=0.4% for HbA1c) in patients with T1D, when 
administered as prandial insulin (0-2 minutes prior to the meal), in combination with basal 
insulin for 26 weeks.  There will be 2 primary analysis methods, each tested at the full 
significance level of 0.05.  
For the US FDA submission, the primary analysis method will use the copy reference approach 
to impute missing data based on multiple imputations with a pattern mixture model.  This 
analysis is for The other primary estimand, requested by the US FDA, will be an the ITT 
estimand (effectiveness/treatment regimen estimand) that will include all data collected from 
randomization through Week 26, regardless of IP use.  The reference will be all observed data 
from the randomized patients in the same treatment group who discontinue IP and complete the 
study without missing data.  After imputation, the primary efficacy comparison will be based on 

I8B-MC-ITRM Clinical Protocol
Page 103
LY900014
the contrast between LY900014 and insulin lispro from the ANCOVA analysis of change from 
baseline to Week 26 in HbA1c using all randomized patients as described in Section 10.3.1.  
If there are only a limited number of patients in the reference group as described above that leads 
to a failure in performing the proposed multiple imputation analysis, the reference will be 
changed to include all observed data from all randomized patients in the same treatment arm who 
complete the study without missing data.  
For non-FDA submissions and publications, Tthe primary efficacy comparison will be based on 
the contrast between LY900014 and insulin lispro at Week 26 (Visit 18) from the MMRM 
analysis of change from baseline in HbA1c usingincluding data collected from all randomized 
patients prior to permanent discontinuation of IP through Week 26 (efficacy estimand).  If the 
upper limit of the 2-sided 95% CI for the LS mean difference in the change from baseline in 
HbA1c for LY900014 minus insulin lispro is below +0.4%, LY900014 will be declared 
noninferior to insulin lispro.  In addition, the 95% CI for the treatment difference from the 
MMRM model will be compared to an alternative NIM of +0.3%.  The analysis model and 
selection of covariance structure is described in Section 10.3.1.  The MMRM analysis will 
include data from all 3 treatment groups; however, the contrasts between LY900014+20 and 
insulin lispro and between LY900014 and LY900014+20 are not part of the primary efficacy 
comparison.
For both primary analysis approaches, LY900014 will be declared noninferior to insulin lispro if 
the upper limit of the 2-sided 95% CI for the LS mean difference in the change from baseline in 
HbA1c for LY900014 minus insulin lispro is below +0.4%.  In addition, the 95% CI for the 
treatment difference will be compared to an alternative NIM of +0.3%.  Both estimands will be 
tested at the full significance level of 0.05.  The ANCOVA and MMRM analyses will include 
data from all 3 treatment groups; however, the contrasts between LY900014+20 and insulin 
lispro and between LY900014 and LY900014+20 are not part of the primary efficacy 
comparisons.
In addition to the primary objective, the superiority of LY900014 in controlling HbA1c 
compared to insulin lispro will also be assessed for each analysis approach described above.  If 
the p-value is less than the alpha level from the graphical approach allocated to the superiority 
hypothesis, LY900014 will be declared superior to insulin lispro.
There will be 2 primary estimands to compare treatment groups for the analysis of the primary 
measure of change from baseline to Week 26 in HbA1c.  One primary estimand will be an 
efficacy estimand that includes only data collected prior to permanent discontinuation of IP 
through Week 26.  Both estimands will use the same primary analysis model, and each will be 
tested at the full significance level of 0.05.  
10.3.3.1.1. Sensitivity Analyses for Missing Data
For the ITT estimand, the reference group will be as described for the FDA primary analysis, and 
ANCOVA on the change from baseline to Week 26 in HbA1c will be used.  

I8B-MC-ITRM Clinical Protocol
Page 104
LY900014
For the efficacy estimand, the reference group will be the insulin lispro treatment group.  
Imputation will be for all longitudinal visits.   
10.3.3.1.2. Additional Analyses for the Primary Endpoint
The primary MMRM analysis model, MMRM, will be repeated using the PP and Completer 
populations to check the sensitivity of the analysis.  If the conclusion differs from that of all 
randomized patients, the data and analyses will be further investigated.  
A secondary analysis model for the efficacy estimand will be an ANCOVA for HbA1c change 
from baseline to Week 26 (Visit 18), using the model described in Section 10.3.1.  Missing 
endpoints will be imputed using the LOCF approach using postbaseline data only.  
In addition to the primary objective, the superiority of LY900014 in controlling HbA1c 
compared to insulin lispro will also be assessed with the same model using all randomized 
patients.  If the p-value is less than the alpha level from the graphical approach allocated to this 
hypothesis, LY900014 will be declared superior to insulin lispro.
10.3.3.2. Secondary Analyses
Analyses will be performed for both the efficacy estimand and ITT estimand as described in 
Section 10.3.3.1 using the same graphical testing scheme.
The graphical testing scheme will be described in the SAP.  The study total alpha level (or study-
wise type I error) is preset to be 5% for each estimand. The study total alpha level will be used 
for the primary objective in the initial step. The alpha level will be allocated to other key 
endpoints based on the weights in testing paths once the primary endpoint is successfully 
demonstrated. If 1 of the remaining hypotheses is successfully demonstrated with the preserved 
alpha level, its preserved alpha will be allocated to the remainder of the hypotheses by the 
weights in the paths. The iterative test procedure continues until none of the remaining 
hypotheses can be demonstrated with their preserved alphas or all hypotheses are demonstrated 
successful.
An ANCOVA model with strata (pooled country, type of basal insulin, patient’s personal CGM 
prandial insulin dosing planuse during the study, and baseline HbA1c strata [(≤7.5%, >7.5%]) 
and treatment as fixed effects and baseline as a covariate will be used to analyze the 1-hour and 
2-hour PPG excursions.  
Superiority in change from baseline in HbA1c for LY900014 compared with insulin lispro and 
noninferiority in change from baseline in HbA1c for LY900014+20 to insulin lispro will be 
determined from the analysis approaches outlined in Section 10.3.3.1.  
HbA1c and change from baseline in HbA1c at all time points will be analyzed by the same 
MMRM model used for the primary analysis for the efficacy estimand.  
Additional continuous secondary efficacy variables, as well as the change from baseline for these 
variables, will be analyzed either by the MMRM or ANCOVA models described in 
Section 10.3.1 for the efficacy estimand.

I8B-MC-ITRM Clinical Protocol
Page 105
LY900014
Analyses of efficacy data collected from randomization through Week 52 for comparisons of the 
LY900014 and insulin lispro treatment groups will be similar to those described above for the 
efficacy estimand.  
10.3.5.2. Subgroup Analyses
•
Prandial insulin dosing plan (carbohydrate counting, pattern adjustment)
•
Patient’s personal CGM/FGM use during the study (Yes, No)
10.3.6. Interim Analyses
Investigators and patients will remain blinded to treatment assignments until the final database 
lock after all patients complete the study as described in Section 7.3.
Appendix 8
Eligibility for Insulin Lispro Antibody Follow-Up Assessment
Study visits will continue at approximately 3 month intervals for a maximum of 1 year6 months
(approximately 48 26 weeks) after Visit 801 or until insulin lispro antibodies return to baseline 
range, whichever occurs sooner.
Visit 802 should occur no sooner thanapproximately 9 13 weeks after Visit 801. to allow time to 
perform antibody testing on the Visit 801 sample.  
In any case, even where insulin antibodies persist, the insulin lispro antibody follow-up 
assessment is expected to last no longer than 52 30 weeks from the protocol-scheduled last 
treatment visit.  
Procedures for Insulin Lispro Antibody Follow-Up Assessment
Blood samples for insulin lispro antibody and HbA1c measurements should be collected at 
approximately 3-month intervals for up to 48 26 weeks after Visit 801.  
Schedule of Activities during Insulin Lispro Antibody Follow-Up Assessment
Study Period 
Insulin Lispro Antibody 
Follow-Up Period
ED-IA 
Follow-Up
eCRF Visit Number
802
803
804
805
Visit Window (days)
±+14
±14
±14
±14
Time on Study Relative to Last Treatment Dose Visit 
(weeks)
1317
2630
39
52
Time on Study Relative to First Treatment Dose Visit 
(weeks)
Open Label:
3943
Double Blind: 
6569
5256
7882
65
91
78
104
IWRS
X
X
X
X
X
Dispense glucose monitoring and ancillary supplies
X
X
X
Telephone call for visit reminder or informing patient of 
completion in the study
X
X
X

I8B-MC-ITRM Clinical Protocol
Page 106
LY900014
Study Period 
Insulin Lispro Antibody 
Follow-Up Period
ED-IA 
Follow-Up
eCRF Visit Number
802
803
804
805
Visit Window (days)
±+14
±14
±14
±14
Time on Study Relative to Last Treatment Dose Visit 
(weeks)
1317
2630
39
52
Time on Study Relative to First Treatment Dose Visit 
(weeks)
Open Label:
3943
Double Blind: 
6569
5256
7882
65
91
78
104
Return of unused diabetes medications and study supplies 
if required by local regulations
X
X
X
X
X
Clinical Assessments
Concomitant medication (including OAMs)
X
X
X
X
X
Total daily prandial insulin dose
X
X
X
X
X
Total daily basal insulin dose
X
X
X
X
X
Vital signs
X
X
X
X
X
Body weight
X
X
X
X
X
Adverse events
X
X
X
X
X
Laboratory Assessments
Anti-insulin lispro antibodies
X
X
X
X
Xa
HbA1c
X
X
X
X
X

PPD
Leo Document ID = 1f72cd6b-be68-47a5-98a5-79f7ac33104d
Approver: 
Approval Date & Time: 22-May-2017 20:32:02 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 22-May-2017 20:39:01 GMT
Signature meaning: Approved
PPD